

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

FINAL PROGRAM

THE 20TH ANNUAL MEETING AND SCIENTIFIC SESSIONS



APRIL 5 – 8, 2000

CONVENING AT THE
OSAKA INTERNATIONAL CONVENTION CENTER
OSAKA, JAPAN

International Society for Heart and Lung Transplantation

BOARD OF DIRECTORS

President

Robert L. Kormos, MD, Pittsburgh, PA

President-Elect

Anne Keogh, MBBS, MD, Sydney, Australia

Past President

Alan H. Menkis, MD, FRCS(C), London, Ontario, Canada

Secretary/Treasurer

Mark L. Barr, MD, Los Angeles, CA

Directors

Linda J. Addonizio, MD, New York, NY

Robert C. Bourge, MD, Birmingham, AL

John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom

Axel Haverich, MD, Hannover, Germany

Marshall Hertz, MD, Minneapolis, MN

Jon Kobashigawa, MD, Los Angeles, CA

Linda Ohler, RN, MSN, Bethesda, MD

Mehmet C. Oz, MD, New York, NY

Stephan Schueler, MD, Dresden, Germany

Lynne Warner Stevenson, MD, Boston, MA

Susan Stewart, FRCPath, Cambridge, United Kingdom

JHLT Editor

James K. Kirklin, MD, Birmingham, AL

Registry Medical Director

Jeffrey D. Hosenpud, MD, Milwaukee, WI

STAFF

Amanda W. Rowe

Executive Director

Phyllis Glenn

Assistant Executive Director

Lisa Ramirez

Director of Meetings

Hope Wiley

Executive Assistant

SCIENTIFIC PROGRAM COMMITTEE

Jon Kobashigawa, MD, Program Chair, Los Angeles, CA
Mark L. Barr, MD, Past Program Chair, Los Angeles, CA
Gerald J. Berry, MD, Stanford, CA
Steven F. Bolling, MD, Ann Arbor, MI
Margaret Burke, MB, MRCPATH, Harefield, United Kingdom
Maria Rosa Costanzo, MD, Chicago, IL
Sabina M. DeGeest, RN, PhD, Basel, Switzerland
Edward R. Garrity, Jr., MD, Maywood, IL
Paul J. Hendry, MD, Ottawa, Ontario, Canada
Gregory M. Hirsch, MD, Halifax, Nova Scotia, Canada
Masatsugu Hori, MD, PhD, Osaka, Japan
Ian V. Hutchinson, PhD, Manchester, United Kingdom
Anne Keogh, MBBS, MD, President-Elect, Sydney, Australia
Walter Klepetko, MD, Vienna, Austria
Karl B. Lemstrom, MD, PhD, Helsinki, Finland
Hikaru Matsuda, MD, Osaka, Japan
Bruno M. Meiser, MD, Munich, Germany
Robert E. Michler, MD, Columbus, OH
Francesco Parisi, MD, Rome, Italy
Nicholas G. Smedira, MD, Cleveland, OH
David O. Taylor, MD, Program Chair Elect, Salt Lake City, UT

JAPAN LOCAL ORGANIZING COMMITTEE

Yasunaru Kawashima, MD, Chairman
Ryota Shirakura, MD, Treasurer
Shigefumi Fujimura, MD
Hajime Hirose, MD
Shigeki Hitomi, MD
Masatsugu Hori, MD
Kazuo Monma, MD
Harubumi Kato, MD
Souichirou Kitamura, MD
Hitoshi Koyanagi, MD
Takayuki Kuriyama, MD
Hikaru Matsuda, MD
Yasumasa Monden, MD
Takeshi Nakatani, MD
Ryozo Omoto, MD
Shigetake Sasayama, MD
Morie Sekiguchi, MD
Akira Taira, MD
Yoshio Yazaki, MD

ABSTRACT REVIEWERS

William T. Abraham, MD, Cincinnati, OH
Michael A. Acker, MD, Philadelphia, PA
Juntaro Ashikari, MS, Tokyo, Japan
Nicholas R. Banner, MD, Harefield, United Kingdom
William A. Baumgartner, MD, Baltimore, MD
Nancy D. Bridges, MD, Philadelphia, PA
Marguerite Brown, RN, MSN, Los Angeles, CA
Shu Hsu Chu, MD, Taipei, Taiwan
John V. Conte, MD, Baltimore, MD
Paul A. Corris, MD, FRCP, Newcastle Upon Tyne, United Kingdom
Sandy A. Cupples, DNSc, Washington, DC
Mary Amanda Dew, PhD, Pittsburgh, PA
Robert A. Dion, MD, Brussels, Belgium
Verdi J. DiSesa, MD, Chicago, IL
John J. Dunning, FRCS, Cambridge, United Kingdom
Jim J. Egan, MD, Manchester, United Kingdom
Thomas M. Egan, MD, MSC, Chapel Hill, NC
Howard J. Eisen, MD, Philadelphia, PA
Roberto Fiocchi, MD, PhD, Bergamo, Italy
Michael C. Fishbein, MD, Los Angeles, CA
Marie L. Foegh, MD, Atlanta, GA
Norihide Fukushima, MD, Osaka, Japan
Elisabeth L. George, RN, Pittsburgh, PA
Martin J. Goddard, FRCSJ, Cambridge, United Kingdom
Steven R. Gundry, MD, Loma Linda, CA
Axel Haverich, MD, Hannover, Germany
Alain Heroux, MD, Chicago, IL
Marshall I. Hertz, MD, Minneapolis, MN
Roland Hetzer, MD, PhD, Berlin, Germany
Hajime Hirose, MD, Gifu, Japan
William L. Holman, MD, Birmingham, AL
Jeffrey D. Hosenpud, MD, Milwaukee, WI
Manfred Hummel, MD, PhD, Berlin, Germany
Silviu Itescu, MD, New York, NY
Tohru Izumi, MD, Kanagawa, Japan
Tiny Jaarsma, RN, Leiden, The Netherlands
Mariell Jessup, MD, Philadelphia, PA
Akira T. Kawaguchi, MD, Isehara, Japan
Akihiko Kawai, MD, Tokyo, Japan
Motohiro Kawauchi, MD, Tokyo, Japan
Shaf Keshavjee, MD, Toronto, Ontario, Canada
James K. Kirklin, MD, Birmingham, AL
Akira Kitabatake, MD, Sapporo, Japan
Satoru Kitagawa-Sakakida, MD, Osaka, Japan
Soichiro Kitamura, MD, Osaka, Japan
Christer Kjellstrom, MD, Goteberg, Sweden
Masayasu Komaki, RN, Osaka, Japan
Petri Koskinen, MD, PhD, Helsinki, Finland
Hitoshi Koyanagi, MD, Tokyo, Japan
Takayuki Kuriyama, MD, Chiba, Japan
Pawel Kwiatkowski, MD, Columbus, OH
Kevin P. Landolfo, MD, Durham, NC
Daniel Y. Loisanche, MD, Creteil, France
Joren C. Madsen, MD, PhD, Boston, MA
Patrick M. McCarthy, MD, Cleveland, OH
Kenneth R. McCurry, MD, Pittsburgh, PA
Mandeep Mehra, MD, New Orleans, LA

Phillippe Menasche, MD, PhD, Paris, France
Dominique Metras, MD, Marseille, France
Leslie W. Miller, MD, Minneapolis, MN
Yasuo Morishita, MD, Gunma, Japan
W. Robert Morrow, MD, Little Rock, AR
Takeshi Nakatani, MD, PhD, Osaka, Japan
Dimitri Novitzky, MD, FCS, Tampa, FL
Shinichi Nunoda, MD, Tokyo, Japan
Ryoto Omoto, MD, Saitama, Japan
Mehmet C. Oz, MD, New York, NY
Walter E. Pae, Jr., MD, Hershey, PA
Frances D. Pagani, MD, PhD, Ann Arbor, MI
Scott Palmer, MD, Durham, NC
Wayne D. Paris, MSW, Oklahoma City, OK
G. Alec Patterson, MD, St. Louis, MO
Richard Pierson, III, MD, Nashville, TN
Branislav Radovancevic, MD, Houston, TX
Stephen P. Rainer, MD, Sydney, Australia
Anne R. Raisanen-Sokolowski, MD, PhD, Helsinki, Finland
Anees Razzouk, MD, Loma Linda, CA
Dale G. Renlund, MD, Salt Lake City, UT
Robert C. Robbins, MD, Stanford, CA
Joseph G. Rogers, MD, St. Louis, MO
Bruce R. Rosengard, MD, Philadelphia, PA
Stuart D. Russell, MD, Durham, NC
Jeanne Salyer, PhD, RN, Richmond, VA
Shigetake Sasayama, MD, Kyoto, Japan
Larry L. Schulman, MD, New York, NY
Robert E. Shaddy, MD, Salt Lake City, UT
Ryota Shirakura, MD, Osaka, Japan
Sara J. Shumway, MD, Minneapolis, MN
Gregory Snell, FRACP, MBE, Prahan, Australia
Randall C. Starling, MD, Cleveland, OH
Henry D. Tazelaar, MD, Rochester, MN
Wolfgang Von Scheidt, MD, Munich, Germany
Florian Wagner, MD, Dresden, Germany
John Wallwork, MBChB, FRCS, Cambridge, United Kingdom
Willem Weimar, Rotterdam, The Netherlands
Lori J. West, MD, PhD, Toronto, Ontario, Canada
Connie White-Williams, MSN, RN, Birmingham, AL
Gayle L. Winters, MD, Boston, MA
Ernst Wolner, MD, Vienna, Austria
Samuel Yousem, MD, Pittsburgh, PA
Chikao Yutani, MD, PhD, Osaka, Japan
Martin R. Zamora, MD, Denver, CO
Adriana Zeevi, PhD, Pittsburgh, PA

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

AWARD RECIPIENTS

LIFETIME SERVICE AWARD

1996 Michael Kaye
1997 Jaques Losman

LIFETIME ACHIEVEMENT AWARD

1999 Keith Reemtsma, MD
1998 Norman Shumway, MD

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Scott D. Ross, MD

ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT

1997 Owen T. Lawrence, MD
1996 Andrew F. Pierre, MD
1995 Frances L. Johnson, MD

ISHLT/ROCHE LABORATORIES TRANSPLANT RESEARCH FELLOWSHIP GRANT

1999 Donald Wong, PhD
Sivasai Krovvidi, PhD
1998 Kelly S.A. Blair, MD
A.M. El Gamel, MD
1997 Jonathen Chen, MD
Anne K. Raisanen-Sokolowski, MD
1996 Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT

1999 George Juang, MD
Satoshi Saito, MD
1998 Margaret L. Schwarze, MD

ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Christine L. Lau, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Alyssa M. Krasinskas, MD

CAVES AWARD

1999 Joerg Koglin, MD
1998 Carla C. Baan, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 Jobst Winter, MD
1994 Alain Chapelier, MD
1993 David Marshman, MD
1992 David P. Kapelanski, MD

1991 A. Jiminez, MD
1990 Andres J. Duncan, MD
1989 A.M. Wood, MD
1988 Charles D. Fraser, Jr., MD
1987 Wim Van Der Bij, MD
1986 Stuart J. Knechtle, MD
1985 Michael A. Breda, MD
1984 Hermann Reichensperner, MD
1983 Robbin G. Cohen, MD

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation:

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 36 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Category I Continuing Education Points for Transplant Coordinators (CEPTS) have been applied for through the American Board of Transplant Coordinators (ABTC).

Category A Continuing Education Units for Nurses have been applied for through the American Association of Critical Care Nurses (AACN).

Disclosure:

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown on page of this program. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives:

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals:

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience:

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives:

At the conclusion of this meeting, participants should be able to:

- * identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
- * compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- * understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- * compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- * describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
- * understand current animal models of basic science immunology and their application to the transplant setting
- * evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
- * understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection

- * identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
- * evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
- * evaluate and implement the use of alternative methods of monitoring and treating rejection
- * identify, prevent, and treat donor-transmitted diseases

DISCLOSURE:

It is the policy of the International Society for Heart and Lung Transplantation to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating in these programs are expected to disclose to the program audiences any affiliations or financial interests related to the content of their presentations.

Faculty Name & Presentation	Company Affiliation	Relationship
Anne Keogh Satellite Symposium 2	Roche Laboratories	Research Support
Alain Heroux Abstract #42	ThermoCardio Systems	Stocks
Helen Whitford Abstract #59	Glaxo Wellcome Australia	Research Support
Anthony De Soyza Abstract #60	3M Pharmaceuticals	Investigational Grant
Kathleen Grady Abstract #87 & 172	ThermoCardio Systems	Stock
Wolfram Beierlein Abstract #96	Jostra Medizintechnik AG	Research Support
Piet Jansen Abstract #109	Baxter Healthcare	Employee
Mehmet Oz Sunrise Symposium 3	Abiomed	Medical Advisory Board
Jeffrey Hosenpud Abstract #144	Roche Laboratories	Financial
Christine Lawless Abstract #151	Smith Kline	Medical Advisory Board
J. David Vega Abstract #165	SangStat	Research Support
Marshall Hertz Abstract #189 & Saturday Debate	Novartis Pharmaceuticals	Medical & Scientific Advisor
Carl Atkinson Abstract #231	Imutran, Cambridge	Technical Contract
Dereck Wheeldon Abstract #252	Baxter Healthcare	Employee

The International Society for Heart and Lung Transplantation
is most grateful for the educational grants and the support of our corporate partners towards this Twentieth Annual
Meeting and Scientific Sessions

PLATINUM PARTNER

Novartis Pharmaceuticals

Roche

Japan Cardiovascular Research Foundation

Pharmaceutical Manufacturers' Association of Tokyo

Osaka Pharmaceutical Manufacturers' Association

GOLD PARTNER

Fujisawa Healthcare, Inc.

Fujisawa GmbH

SILVER PARTNER

SangStat Medical Corporation

BRONZE PARTNER

MedImmune

CORPORATE SUPPORTER

Baxter Healthcare-Novacor Division

Bayer

Japan Association for Heart Transplantation

Japan Association for Lung Transplantation

Osaka Convention Bureau

Therakos

International Society for Heart and Lung Transplantation
Twentieth Annual Meeting and Scientific Sessions
April 5-8, 2000
Osaka, Japan

Note: Those sessions marked with an asterisk will be translated from English into Japanese. All presentations will be in English. All meetings and activities will take place at the Osaka International Convention Center unless otherwise noted.

Wednesday, April 5, 2000

7:00 am-9:00 am
ISHLT Editorial Board Meeting (Diamond Room, Rihga Royal Hotel)

8:00 am-5:00 pm
Exhibitor Set Up (Event Hall 2)

8:00 am-Noon
ISHLT Board of Directors Meeting (Sapphire Room, Rihga Royal Hotel)

10:00 am-7:00 pm
Registration (Main Foyer)

10:00 am-Noon
Registry Committee Meeting (Diamond Room, Rihga Royal Hotel)

Noon-5:00 pm
Poster Session 1 Set-Up (Event Hall 2)

12:30 pm-3:00 pm
Satellite Symposium 1: Introduction to Clinical Heart Transplantation: Pre-Operative Issues* (Convention Hall)

Moderators: Robert L. Kormos, MD, and Leslie W. Miller, MD

12:30 pm *Ethics and Religious Beliefs*, James Young, MD, Cleveland Clinic Foundation, Cleveland, OH

1:00 pm *Donor Appropriation and Preservation*, Hillel Laks, MD, University of California, Los Angeles, CA

1:30 pm *Evaluation of the Heart Failure Patient for Heart Transplantation*, Lynne W. Stevenson, MD, Brigham and Women's Hospital, Boston, MA

2:00 pm *Surgical Procedures*, Alan H. Menkis, MD, London Heath Sciences Center, London, Ontario, Canada

2:30 pm *Physiology of the Transplanted Heart and Pacing Needs*, Jon Kobashigawa, MD, University of California, Los Angeles, CA

12:30 pm-3:00 pm
Satellite Symposium 2: Journey Through the Universe of Heart Failure: From the Genes to the Office (Room 1001-1003)

Moderators: Maria Rosa Costanzo, MD, and Anne Keogh, MD

12:30 pm *The Black Box of Remodeling: Genes, Proteins, and Cytokines*, Guillermo Torre-Amione, MD, PhD, Baylor College of Medicine, Houston, TX

1:00 pm *The Long Road to Optimal Medical Practice: Are We There Yet?*, Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

1:30 pm *Journey Through the Next Generation of Drug Therapy: Natriuretic Peptides, Endothelin Inhibitors, and Cytokine Antagonists*, William Abraham, MD, University of Cincinnati, Cincinnati, OH

2:00 pm *The Wagon of Resynchronization: How Far Will it Take us in the Management of Chronic Heart Failure?* Vince Paul, MD, Middlesex, United Kingdom

2:30 pm *Inside the Heart Failure Program: Infrastructure and Economics*, Maria Rosa Costanzo, MD, Rush Presbyterian St. Luke's Medical Center, Chicago, IL

3:00 pm-3:30 pm Coffee Break (Foyer in front of Room 1001-1003)

3:30 pm–6:00 pm

Satellite Symposium 3: Introduction to Clinical Heart Transplantation: Post-Operative Issues* (Convention Hall)

Moderators: Jack Copeland, MD, and Sharon Hunt, MD

3:30 pm *Basic Transplant Immunology, Immunosuppression Strategies, and Regimens*, Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

4:00 pm *Rejection and Infection*, Robert C. Bourge, MD, University of Alabama, Birmingham, AL

4:30 pm *Psychosocial Issues Post Heart Transplant*, Mary Amanda Dew, PhD, University of Pittsburgh, Pittsburgh, PA

5:00 pm *Metabolic Problems: Osteoporosis, Hyperlipidemia, Hypertension, Renal Insufficiency*, Jayan Parameshwar, MD, Papworth Hospital, Cambridge, United Kingdom

5:30 pm *Transplant Coronary Artery Disease*, Hannah Valentine, MD, Stanford University, Palo Alto, CA

3:30 pm–6:00 pm

Satellite Symposium 4: Variations on a Theme: Alternatives to Standard Cadaveric Lung Transplants (Room 1001-1003)

Moderators: Mark Barr, MD, and Ed Garrity, MD

3:30 pm *Pulmonary Fibrosis and Cystic Fibrosis: Emerging and Novel Therapies*, Keith McNeil, MD, Papworth Hospital, Cambridge, United Kingdom

4:00 pm *Pulmonary Hypertension: Alternatives to Intravenous Therapy*, Dr. Werner Seeger, MD, Medizinische Klinik Giessen, Giessen, Germany

4:30 pm *Lung Volume Reduction for Emphysema*, Robert Keenan, MD, University of Pittsburgh, Pittsburgh, PA

5:00 pm *Pulmonary Thromboendarterectomy, Split Cadaveric, and Living Donor Lobar Transplants*, Walter Klepetko, MD, University of Vienna, Vienna, Austria

6:00 pm–7:00 pm

Exhibits Open

Wine and Cheese Reception (Main Foyer)

Thursday, April 6, 2000

7:00 am–10:00 am

Poster Session 1 Set-Up (Event Hall 2)

7:00 am–6:30 pm

Registration (Main Foyer)

7:00 am–8:00 am

Morning Coffee/Continental Breakfast (Event Hall 2)

7:00 am–6:30 pm

Exhibits Open (Event Hall 2)

8:00 am–10:00 am (Convention Hall)

Opening Plenary Session*

Moderators: Robert L. Kormos, MD, and Jon Kobashigawa, MD

8:00 am *Welcome*, Robert L. Kormos, MD, ISHLT President, University of Pittsburgh, Pittsburgh, PA

8:10 am *Local Welcome*, Yasunaru Kawashima, MD, Chairman, Japan Local Organizing Committee, National Cardiovascular Center, Osaka, Japan

8:15 am *Scientific Program Report*, Jon Kobashigawa, MD, ISHLT Scientific Program Chair, University of California, Los Angeles, CA

8:30 am *Registry Report*, Jeffrey D. Hosenpud, MD, Registry Medical Director, University of Wisconsin, Milwaukee, WI

8:45 am *Pioneers in Transplantation Lecture*, Norman Shumway, MD, Stanford University, Palo Alto, CA

9:15 am *Invited Lecture: Tolerance*, Thomas D. Wekerle, MD, University of Vienna, Vienna, Austria

9:45 am *Featured Abstract (1) Intermediate Term Results of the Alternate Recipient List for Heart Transplantation*, H. Laks, D. Marelli, D. Fazio, A. Sadeghi, A. Ardehali, M. Hamilton, J. Moriguchi, G. Fonarow, A. Hage, F. Esmailian, N. Kawata, J. Kobashigawa, University of California, Los Angeles, CA

10:00 am-10:30 am

Coffee Break/Visit Exhibits/View Posters (Event Hall 2)

10:30 am-Noon

Concurrent Session 1

Clinical Heart Transplantation 1: Allograft Rejection* (Convention Hall)

Moderators: Bruno Reichart, MD, and David Taylor, MD

10:30 am (2) *The Crossmatch in Cardiac Transplantation: Relative Risks*, D.J. Cook, E. Bishay, R.C. Starling, J.B. Young, N. Smedira, P.M. McCarthy, The Cleveland Clinic Foundation, Cleveland, OH

10:45 am (3) *FlowpraTM, Flow Cytometric Crossmatch and HLA-DR Matching are Predictors of Early Rejection Episodes in Cardiac Transplantation*, R.A. Bray, C.L. D'Amico, K.R. Kanter, A.L. Smith, L. Wilmoth-Hosey, A. Berg, J.D. Vega, Emory University, Atlanta, GA

11:00 am (4) *Recipient HLA-B8, DR3, Type is Associated With Increased Risk for High-Grade Acute Rejection in Cardiac Allograft Recipients*, K. Lietz, E. Burke, A. Kocher, N. Suci-Foca, D. Mancini, N. Edwards, S. Itescu, Columbia University, New York, NY

11:15 am (5) *Telemedicine: A New Implantable Multisensor Device for Non-Invasive Transtelephonic Monitoring of Cardiac Recipients*, J. Mueller, F. Kaufmann, M. Dandel, O. Grauhan, Y. Weng, M. Pasic, K. Kalanaki, M. Bettmann, R. Wenzel, S. Spiegelsberger, M. Hummel, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany

11:30 am (6) *Recovery of Left Ventricular Function is More Delayed in Cardiac Transplant Recipients With Non-Cellular (Humoral) Rejection than in Recipients With Cellular Rejection*, R. Sangrigoli, H.J. Eisen, Temple University, Philadelphia, PA

11:45 am (7) *Predictive Value of Combined Indices of Diastolic and Systolic Myocardial Performance to Identify Cardiac Allograft Rejection*, K. Vivekananthan, T. Kalapura, M.H. Park, R.L. Scott, R.V. Milani, M.R. Mehra, Ochsner Heart and Vascular Institute, New Orleans, LA

10:30 am-Noon

Concurrent Session 2

Donor Management, Preservation, and Organ Distribution 1: Experimental (Room 1001-1003)

Moderators: Hikaru Matsuda, MD, and Alec Patterson, MD

10:30 am (8) *The Effect of Cyclooxygenase 2 Inhibitor, FK3311, on Ischemia-Reperfusion Injury in Canine Lung Transplantation*, Y. Sunose, I. Takeyoshi, S. Ohwada, S. Iwazaki, M. Aiba, N. Tomizawa, H. Tsutsumi, N. Oriuchi, K. Matsumoto¹, Y. Morishita, Gunma University School of Medicine, Maebashi, and ¹Nippon Medical School, Kawasaki, Japan

10:45 am (9) *Pre-Treatment of the Donor Lungs With Inhaled Nitric Oxide Reduces Endothelial Leakage and Neutrophil Sequestration*, C.D. Sudarshan, A. Bell, P.A. Flecknell, B.K. Shenton, J.H. Dark, Cardiothoracic Centre, Freeman Hospital, and the Department of Surgery, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom

11:00 am (10) *A Novel Strategy of Prolonged Myocardial Preservation Using Gene Transfection of Cis Element "Decoy" Against Nuclear Factor- κ B Binding Site*, Y. Sawa, T. Sakaguchi, N. Fukushima, M. Nishimura, H. Matsuda, Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

11:15 am (11) *Extending Myocardial Viability During Heart Preservation With Cyclosporine A*, T.N. Masters, A.A. Fokin, F. Robicsek, J. Schaper, S. Lorenz-Meyer, L. Pool, Heineman Medical Research Center, Charlotte, NC, and Max-Planck-Institute for Physiological and Clinical Research, Bad Nauheim, Germany

11:30 am (12) *Inhaled Nitric Oxide Over the First Ten Minutes of Lung Reperfusion Compared With Later Exposure Attenuates Acute Lung Injury in a Transplant Model*, C.D. Sudarshan, S.C. Clark, P.A. Flecknell, S. Haynes, J.H. Dark, Cardiothoracic Centre, Freeman Hospital, and University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom

11:45 am (13) *FK409 Ameliorates Ischemia-Reperfusion Injury in Heart Transplantation Following 12-Hr Cold Preservation*, J. Mohara, K. Oshima, H. Tsutsumi, I. Takeyoshi, S. Ishikawa, K. Matsumoto¹, Y. Morishita, Gunma University School of Medicine, Maebashi, and ¹The Second Hospital of Nippon Medical School, Kawasaki, Japan

10:30 am – Noon

Concurrent Session 3

Pathology (Event Hall 1)

Moderators: Michael C. Fishbein, MD, and Margaret Burke, MD

10:30 am (14) *Altered Expression of Matrixmetalloproteinases in Rejected Cardiac Allografts of Non-Human Primates*, J. Suzuki, M. Isobe, M. Kawauchi, M. Aikawa, T. Nishikawa, J. Amano, S. Takamoto, P. Libby, Shinshu University, Nagano; Tokyo Medical and Dental University, Tokyo; University of Tokyo, Tokyo; Tokyo Women's Medical University, Tokyo, Japan; and Harvard Medical School, Boston, MA

10:45 am (15) *Expression of Membrane-Type 1 Matrix Metalloproteinase in Coronary Vessels of Allografted Primate Hearts*, K. Tsukioka¹, J. Suzuki², M. Kawauchi³, Y. Wada¹, T. Zhang¹, N. Koide¹, M. Endoh³, K. Takayama¹, S. Takamoto³, M. Isobe², J. Amano¹, ¹the Second Department of Surgery and ²the First Department of Internal Medicine, Shinshu University, Nagano, and ³the Department of Thoracic Surgery, University of Tokyo, Tokyo, Japan

11:00 am (16) *Rantes Expression and Leukocyte Phenotype Distinguish Acute Cellular Rejection (ACR) From Quilty B Lesions (QB)*, P.J. Michaels, M.C. Fishbein, A. Azarbal, M.L. Espejo, L. Chen, H. Laks, J. Kobashigawa, Pathology, Medicine, and Cardiothoracic Surgery, University of California, Los Angeles, CA

11:15 am (17) *Intragraft CD4+, CD8+T Cells are not Required for Rantes Production Early in Cardiac Allograft Vasculopathy*, J.J. Yun, M.P. Fischbein, H. Laks, M.C. Fishbein, M.L. Espejo, Y. Irie, J. Berliner, A. Ardehali, University of California, Los Angeles, CA

11:30 am (18) *Perlecan Expression Associates With Antithrombin Binding and Outcome in Heart Transplant Recipients*, C.A. Labarrere, S.J. Miller, J.A. Conner, D.R. Nelson, Methodist Research Institute, Clarian Health, Indianapolis, IN, and Cleveland Clinic Foundation, Cleveland, OH

11:45 am (19) *Skeletal Muscle Allograft Surveillance Predicts Chronic Vascular Rejection After Heart Transplantation*, M. Massad, M. Sekosan, J. Blanchard, L. Cicalese, A.S. Geha, E. Benedetti, The University of Illinois, Chicago, IL

Noon-12:45 pm

Box Lunch Pick-up (Event Hall 2)

Noon – 2:00 pm

Visit Exhibits/View Posters (Event Hall 2)

12:15 pm-1:30 pm

Mid-Day Workshop 1: Strategies to Increase the Donor Supply (Room 1001-1003)

Marti Manyalich, MD, Barcelona Hospital, Barcelona, Spain

John Wallwork, MBChB, FRCS, Papworth Hospital, Cambridge, United Kingdom

12:15 pm–1:30 pm

Mid-Day Workshop 2: High Risk Candidates for Heart Transplantation: Pushing the Envelope (Event Hall 1)

James K. Kirklin, MD, University of Alabama, Birmingham, AL

Keith Aaronson, MD, University of Michigan Medical Center, Ann Arbor, MI

12:30 pm–1:45 pm

Mid-Day Workshop 3: Core Curriculum: How to Evaluate a Transplant Candidate* (Convention Hall)

Robert C. Bourge, MD, University of Alabama, Birmingham, AL

Wolfgang Von Scheidt, MD, University of Munich, Munich, Germany

12:15 pm-1:45 pm

Mini Oral Poster Presentation Session 1 (Room 1009)

Moderators: Mandeep Mehra, MD, and Stephan Schueler, MD

12:15 pm (20) *Safety and Efficacy of Atorvastatin in Heart Transplant Recipients*, D.N. Patel, F.D. Pagani, T.M. Koelling, D.B. Dyke, D.R. Armstrong, J.A. Haroldson, K.D. Lake, R.J. Cody, K.D. Aaronson, University of Michigan, Ann Arbor, MI

12:21 pm (21) *Effect of Folate and Pyridoxine Supplementation on Endothelial Function in Cardiac Transplant Recipients*, S.E.S. Miner, D.E.C. Cole, S.J. Hutchison, J. Evrovski, H.J. Ross, The University of Toronto, Toronto, Ontario, Canada

12:27 pm (22) *Homocysteinemia Increases During the Follow Up in Heart Transplanted Patients and it is Associated to Graft Vascular Disease*, L. Potena, C. Magelli, G. Magnani, V. Carinci, L. Marinucci, S. Sorbello, A.M. Bargossi¹, S. Sassi², S. Coccheri², A. Branzi, Institute of Cardiovascular Disease, ¹Department of Clinical Chemistry, and ²Institute of Angiology, University of Bologna, Bologna, Italy

12:33 pm (23) *Impact of Plasma Homocysteine on the Development of Graft Vessel Disease After HTx*, J. Schirmer, B.M. Meiser, M. Bogeser, W. von Scheidt, H. Treede, T. Scheersoi, P. Cremer, B. Reichart, Ludwig-Maximilians-University, Munich, Germany

12:39 pm (24) *Cost Effects of New Immunosuppression Agents*, N. Caine, L.D. Sharples, G. Taylor, J. Karnon, M. Buxton, K. McNeil, J. Wallwork, Papworth Hospital NHS Trust, Cambridge; MRC Biostatistics Unit, Cambridge; and Health Economics Research Group, Brunel University, Uxbridge, United Kingdom

12:45 pm (25) *Long Term Effects of Medical Insurance on Heart Transplant Recipients*, J.D. Moriguchi, D. Devereaux, J.A. Kobashigawa, S. Lackey, R. Camara, A. Velleca, M. Marks, M. Brown, J.M. Chuang, N. Kawata, H. Laks, University of California, Los Angeles, CA

12:51 pm (26) *How Expensive is Heart Transplantation (HTx) When Compared With the Treatment of End Stage Heart Failure (ESHF) Before HTx? A Single Center Analysis of 350 Patients*, M. Hummel, I. Michauk, R. Hetzer, German Heart Institute, Berlin, Germany

12:57 pm (27) *The Effect of Conversion From Cyclosporin to Tacrolimus Based Immunosuppression in Patients Who Develop Bronchiolitis Obliterans Syndrome*, J.W. Cairn, N.R. Banner, M.E. Hodson, M. Yacoub, Department of Transplant Medicine, Royal Brompton Hospital and Harefield NHS Trust, Harefield Hospital, Harefield, United Kingdom

1:03 pm (28) *An Anti-Allergic Agent, Tranilast, Decreases Development of Obliterative Airway Disease in a Rat Model of Heterotopic Tracheal Transplantation*, Y. Okada, T. Kondo, Y. Matsumura, K. Shimada, T. Oyaizu, S. Fujimura, Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

1:09 pm (29) *NKH477, A Forskolin Derivative, Inhibits Acute Rejection in Rat Recipient of Orthotopic Lung Allografts*, S. Nakashima, M. Morikawa, K. Komatsu, T. Abe, Sapporo Medical University, Sapporo, Hokkaido, Japan

1:15 pm (30) *Liposome-Mediated Gene Transfection of ECNOS Reduces Intimal Lesion Formation, Macrophage and T-Lymphocyte Infiltration in Transplant Arteriopathy*, A. Iwata, S. Sai¹, G.C. Quetingco², G.S. Koe², M.D. Allen, Division of Cardiothoracic Surgery, University of Washington, Seattle, WA; ²Valentis Corporation, Burlingame, CA; and ¹Tohoku University, Sendai, Japan

1:21 pm (31) *Adenoviral ENOS+SOD Increases Nitric Oxide Production and Reduces Cardiac Allograft Reperfusion Injury*, D.N. Miniati, E.G. Hoyt, K. Penta, M.D. Kuo, M.D. Dake, T. Quertermous, R.C. Robbins, Stanford University, Stanford, CA

1:27 pm (32) *Estrogen Receptor Mediates Inhibition of Transplant Arteriosclerosis by E2 Through Decreasing IGF-I Receptor Expression in Rat Allograft Aorta*, H. Lou, S. Saito, R. Aras, M.L. Foegh, P.W. Ramwell, Georgetown University Medical Center, Washington, D.C.

1:33 pm (33) *VLA 4 Blockade is Essential in the Prevention of Chronic Rejection After Cardiac Transplantation in Rats*, M. Richter, V. Wehner, I. Waligura, D. Schramm, M. Kock, A. Tannapfel, V. Falk, H. Richter, F.W. Mohr, Herzzentrum, Universitat Leipzig, Leipzig, Germany

1:39 pm (34) *Correlation of Initial T-Cell Response and the Progression of Cardiac Allograft Vasculopathy (CAV) in Retransplanted Rat Heart*, Z. Li, S. Kitagawa-Sakakida, M. Tori, K. Horiguchi, H. Izutani, R. Shirakura, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

2:00 pm-3:30 pm

Concurrent Session 4

Immunosuppression 1: Day to Day Choices* (Convention Hall)

Moderators: Howard Eisen, MD, and Akihiko Kawai, MD

2:00 pm (35) *Is Trough Level Adjusted Mycophenolate Mofetil Administration More Efficacious in Combination With Tacrolimus or With Cyclosporine?* B.M. Meiser, T. Scheersoi, M. Pfeiffer, H. Treede, J. Schirmer, D. Paulus, J. Koglin, H. Reichenspurner, W.V. Scheidt, B. Reichart, University of Munich, Grosshadern Medical Center, Munich, Germany

2:15 pm (36) *Two Year Results of a Double-Blind, Randomized, Multicenter, International Study of Microemulsion vs Oil-Based Cyclosporine in De Novo Heart Transplant Patients*, H.J. Eisen, E.A. Mueller¹, B. Mellein¹, R.E. Hobbs², on behalf of the OLN 351 Study Group, Temple University, Philadelphia, PA; ¹Novartis Pharma Ag, Basel, Switzerland; and ²Cleveland Clinic Foundation, Cleveland, OH

2:30 pm (37) *First Year Results of a Randomized Trial of Tacrolimus vs. Neoral Cyclosporine in Heart Transplant Patients*, J.A. Kobashigawa, J.D. Moriguchi, S. Takemoto, J.M. Chuang, L. Wener, L. Yeatman, T. Ro, D. Deveriaux, N. Kawata, H. Laks, University of California, Los Angeles, CA

2:45 pm (38) *A Randomised, Multicenter Dose Finding Study of Tacrolimus in Cardiac Transplantation*, N.A. Yonan for the European Tacrolimus Heart Study Group, Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom

3:00 pm (39) *Blood Eosinophil Count Monitoring is a Simple, Cheap, Safe and Effective Means of Reducing Heart Allograft Rejection*, A.K. Trull, L.A. Steel, L. Sharples, J. Parameshwar, N. Cary, J. Wallwork, S. Large, Papworth Hospital NHS Trust, Cambridge, United Kingdom

3:15 pm (40) *Induction Therapy in Lung Transplantation: A Comparison of OKT3, ATGAM and Zenapax*, J.V. Conte, L. Ferber, M.C. Borja, S.P. Gaine, S.C. Yang, J.B. Orens, Johns Hopkins Hospital, Baltimore, MD

2:00 pm-3:30 pm

Concurrent Session 5

Clinical Heart Failure 1: Selection and Management of Candidates for Heart Transplantation (Room 1001-1003)

Moderators: Tohru Izumi, MD, and Donna Mancini, MD

2:00 pm (41) *Heart Failure Survival Model Predicts Survival When Applied Serially at Subsequent Reevaluation*, K.D. Aaronson, D.M. Mancini, University of Michigan, Ann Arbor, MI, and Columbia University, New York, NY

2:15 pm (42) *Vanishing Role of Continuous Inotropic Support as a Bridge to Heart Transplantation*, A. Heroux, P. Meyer, W. Kao, L. Bartlett, E. Hung, E. Winkel, M. Saltzberg, M.R. Costanzo, Rush Medical College, Chicago, IL

2:30 pm (43) *Why are Patients Removed From the Heart Transplant Waiting List: Changing Trends From 1994-1998*, M.T. Saltzberg, N. Burke, A.H. Heroux, W.G. Kao, E.M. Windel, M.R. Costanzo, Rush Medical College, Chicago, IL

2:45 pm (44) *Stimulation of Angiogenesis in Explanted Hearts From Patients Pretreated With Intravenous Prostaglandin E1*, M.R. Mehrabi, C. Ekmekcioglu, B. Stanek, T. Thalhammer, F. Tamaddon, R. Paher, K. Plesch, M. Grimm, P.G. Spiekermann, G. Mall, H.D. Glogar, University of Vienna, Vienna, Austria, and University of Darmstadt, Darmstadt, Germany

3:00 pm (45) *Changes in Natriuretic Peptide Levels in Long-Term Catecholamine Infusion for Patients Waiting for Heart Transplantation: A Comparison With Ventricular Assist System*, K. Komamura, K. Miyatake, T. Nakatani, Y. Sasako, T. Yagihara, S. Kitamura, National Cardiovascular Center, Suita, Osaka, Japan

3:15 pm (46) *Prognostic Value of Serial Big Endothelin Plasma Levels in Patients Bridged With Dobutamine or Prostaglandin E1*, B. Stanek, B. Frey, A. Bojic, B. Sturm, E. Moser, E. Hartter, M. Grimm, G. Laufer, R. Pacher, University of Vienna, Vienna, Austria

2:00 pm–3:30 pm

Concurrent Session 6

Basic Science and Immunobiology 1: Cellular Mechanisms (Event Hall 1)

Moderators: Richard N. Pierson, III, MD, and Willem Weimar, MD

2:00 pm (47) *Disruption of B7-1 Costimulation Reduces Graft Coronary Artery Disease in Mice*, Y. Furukawa, D.A. Mandelbrot, P. Libby, A.H. Sharpe, R.N. Mitchell, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

2:15 pm (48) *Endothelium Plays a Minor Role in Acute Murine Cardiac Rejection*, A.M. Krasinskas, D. Kreisel, S.D. Eiref, A.D. McLean, W.Y. Szeto, G. Zheng, Z. Wu, S.H. Popma, B.R. Rosengard, University of Pennsylvania Health System, Philadelphia, PA

2:30 pm (49) *Characterization of T Cells Reactive to Donor HLA Peptides Following Human Lung Transplantation*, K.S.R. SivaSai, E.P. Trulock, J.P. Lynch, G.A. Patterson, T. Mohanakumar, Washington University School of Medicine, St. Louis, MO

2:45 pm (50) *Donor Bone Marrow Cells and Donor Splenocytes Augment Allograft Survival by Distinct Molecular Mechanisms*, J.F. George, D.R. Goldstein, T. Chang, J.K. Kirklin, J.M. Thomas, Departments of Surgery and Medicine, University of Alabama, Birmingham, AL

3:00 pm (51) *Immunological Monitoring of the Beneficial Effect of HLA-DR Shared Blood Transfusion on Graft Survival After Clinical Heart Transplantation*, L.M. Vaessen, P.C. van Miert, K. Doumaid², B.J. van der Mast, A.P. Maat¹, A.H. Balk¹, C.J. Boog², W. Weimar, Department of Internal Medicine 1 and ¹Thorax Center, University Hospital Dijkzigt, Rotterdam, and ²Department of Transplant Immunology, CLB, Amsterdam, The Netherlands

3:15 pm (52) *Recipient Cells Form the Intimal Proliferative Lesion in Allograft Arteriosclerosis*, P.M. Johnson, M.S. Carpenter, T.D.G. Lee, G.M. Hirsch, Dalhousie University, Halifax, Nova Scotia, Canada

3:30 pm–4:00 pm

Coffee Break/Visit Exhibits/View Posters (Event Hall 2)

4:00 pm–5:30 pm

Concurrent Session 7

Clinical Heart Transplantation 2: Borderline Candidates and Long-Term Outcomes* (Convention Hall)

Moderators: Hillel Laks, MD, and Bruno Meiser, MD

4:00 pm (53) *Heart Transplantation for AL Amyloidosis*, C.G.A. McGregor, R.J. Rodeheffer, R.C. Daly, R.A. Kyle, M.A. Gertz, B.S. Edwards, L.J. Olson, R.P. Frantz, J.A. Dearani, Mayo Clinic, Rochester, MI

4:15 pm (54) *"Expanded" Cardiac Allograft Transplantation: Long-Term Results*, S. Murali, T.R. Tokarczyk, J. Ristich, K. McCurry, G.A. MacGowan, W.D. Rosenblum, D.M. McNamara, R.L. Kormos, University of Pittsburgh Medical Center, Pittsburgh, PA

4:30 pm (55) *Long-Term Results of the Use of Hearts From Older Donors: A 13 Year Follow-Up*, E.V. Potapov, M. Loebe, M. Hummel, C. Knosalla, Y. Weng, R. Meyer, R. Hetzer, Berlin, Germany

4:45 pm (56) *Death After Heart Transplantation: A Competing Outcomes Analysis*, C.W. Yancy, D.C. Naftel, B.A. Foley, J.A. Kobashigawa, D.E. Pitts, R.J. Rodeheffer, D.G. Renlund, G. Ewald, G. Kaiser, D.C. McGiffin, for the Cardiac Transplant Research Database (CTRD) Group, University of Alabama, Birmingham, AL

5:00 pm (57) *Cognitive Brain Function Dramatically Decreases in Long Term Survivors After Successful Cardiac Transplantation*, M. Czerny, J. Kilo, H. Baumer, L. Kramer, C. Madl, S. Taghavi, A. Zuckerman, J. Ankersmit, G. Laufer, M. Grimm, University of Vienna, Vienna, Austria

5:15 pm (58) *Post-Transplant Lymphoproliferative Disorders (PTLD) After Heart Transplantation (HTX): Clinical Course, Response to Treatment and Outcome in a Group of 13 Patients*, G. Comerio, E.G. Gonda, G. Muti¹, S. Cantoni¹, B. Andreauzzi, M. Frigerio, M. Mangiavacchi, F. Oliva, E. Morra¹, "A De Gasperis" Cardiac Surgery and Cardiology Centre, Heart Failure and Cardiac Transplant Program, and ¹Hematology Centre, Niguarda Ca' Granda Hospital, Milan, Italy

4:00 pm–5:30 pm

Concurrent Session 8

Lung/Heart-Lung Transplantation 1: The Airway as a Route for Drug Delivery (Room 1001-1003)

Moderators: Paul Corris, MD, FRCP, and Greg Snell, FRACP, MBBS

4:00 pm (59) *Inhaled Fluticasone Propionate (FP) Does Not Alter Inflammation in the Airway of Lung Allografts: A Double Blind Placebo Controlled Trial*, H.M. Whitford, B. Orsida, C. Ward, E.H. Walters, T.J. Williams, T. Kotsimbos, G.I. Snell, Alfred Hospital and Monash Medical School, Prahran, Victoria, Australia

4:15 pm (60) *The Effect of Inhaled Steroids on Inflammatory Markers Associated With Obliterative Bronchiolitis*, A. DeSoyza¹, A.J. Fisher¹, G. Pritchard¹, P.A. Corris^{1,2}, Departments of ¹Respiratory Medicine and ²Cardiopulmonary Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

4:30 pm (61) *The Effect of Aerosol Cyclosporine Prophylaxis on Intra-graft Cytokine Gene Expression in Lung Transplant Recipients*, A. Zeevi, M. Pavalakis, J. Cai, S. Chang, K. Spichy, A. Lacono, J. Dauber, W. Grgurich, R. Keenan, S. Yousem, G. Burckart, K. McCurry, B. Griffith, University of Pittsburgh, Pittsburgh, PA

4:45 pm (62) *Preserved Long-Term Efficacy of Iloprost Inhalation Therapy Over 12 Month in Patients With Primary Pulmonary Hypertension*, R. Wensel, C.F. Opitz, R. Ewert, L. Bruch, R. Hetzer, Deutsches Herzzentrum Berlin, and Unfallkrankenhaus Berlin, Berlin, Germany

5:00 pm (63) *Disposition of Amphotericin B (AMB) Following Aerosol Inhalation in Lung Transplant Recipients*, N. Partovi, F. Marra, K.M. Wasan, M.H.H. Ensom, S. Cassidy, G. Fradet, R.D. Levy, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada

5:15 pm (64) *Pharmacokinetics and Distribution of Nebulized Amphotericin B (n-Amp) in Lung Transplantation*, A. Roman, V. Monforte, J. Gavaldà¹, R. López², L. Pou², M. Simó², S. Aguadé², B. Soriano², C. Bravo, A. Pahissa¹, F. Morell, Serveis de Pneumologia,¹Malalties Infeccioses,²Bioquímica, Medicina Nuclear, Hospital General Vall d'Hebron, Barcelona, Spain

4:00 pm–5:30 pm

Concurrent Session 9

Basic Science and Immunobiology 2: TGF Beta (Event Hall 1)

Moderators: Ian Hutchinson, PhD, and Axel Haverich, MD

(65) WITHDRAWN

4:00 pm (239) *Polymorphisms in the TGF- β 1 Gene in Relation to Renal Dysfunction After Clinical Heart Transplantation*, C.C. Baan, A.H.M.M. Balk, C.T.J. Holweg, I.C. Van Riemsdijk, P.J.M.J. Vantrimpont, A.P.W.M. Maat, H.G.M. Niesters, W. Weimar, Departments of Internal Medicine, Cardiology, and Thoracic Surgery, Diagnostic Institute of Molecular Biology, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands

4:15 pm (66) *TGF- β 1 Protects Against Coronary Artery Disease Before and After Clinical Heart Transplantation*, C.T.J. Holweg, C.C. Baan, H.G.M. Niesters, P. Vantrimpont, A.P.W.M. Maat, A.H.M.M. Balk, W. Weimar, Departments of Internal Medicine 1, Diagnostic Institute of Molecular Biology, Cardiology and Thoracic Surgery, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands

4:30 pm (67) *A Low Producing TGF- β Allele in the Donor or Recipient Genotype Protects from Cardiac Transplant Vasculopathy*, C.G. Densem, I.V. Hutchinson¹, N. Yonan², S. Sheldon¹, N.H. Brooks², ¹Department of Immunology, Wythenshawe Hospital, and ²Manchester University, Manchester, United Kingdom

4:45 pm (68) *Predominant Cytokine Genotypes Associated With Chronic Rejection and Chronic Rejection-Free States in Heart But Not Lung Recipients*, N.L. Reinsmoen, K. Savik¹, S. Ormaza¹, M. Hertz¹, L. Miller¹, A. Jackson, Duke University Medical Center, Durham, NC, and ¹University of Minnesota, Minneapolis, MN

5:00 pm (69) *Transforming Growth Factor Beta and Diastolic Left Ventricular Dysfunction Following Heart Transplantation: Echocardiographic and Histological Evidence*, T.M. Aziz, M.I. Burgess, P.S. Hasleton, N.A. Yonan, A.K. Deiraniya, A.N. Rahman, C.S. Campbell, I.V. Hutchinson, Cardiac Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom

5:15 pm (70) *Conversion From Cyclosporine to Tacrolimus Downregulates the TGF- β System and Improves Renal Function, Cholesterol Levels and Blood-Pressure in Heart Transplant Recipients*, I.C. van Riemsdijk, C.C. Baan, C.J. Knoop, A.H.M.M. Balk, P.J.M.J. Vantrimpont, A.P.W.M. Maat, W. Weimar, Department of Internal Medicine, Cardiology and Thoracic Surgery, University Hospital Rotterdam, Rotterdam, The Netherlands

5:30 pm-6:30 pm

Moderated Poster Session 1/Wine and Cheese Reception (Event Hall 2)

(see end of program for list of poster titles)

6:30 pm-7:30 pm

Poster Session 1 Tear-Down (Event Hall 2)

7:00 pm-8:00 pm

Corporate Council Reception (Emerald Room, Rihga Royal Hotel)

Friday, April 7, 2000

6:30 am-5:00 pm

Registration (Main Foyer)

6:30 am-6:30 pm

Exhibits Open (Event Hall 2)

6:30 am-8:00 am

Morning Coffee/Continental Breakfast (Event Hall 2)

6:30 am-10:00 am

Poster Session 2 Set-Up (Event Hall 2)

6:45 am-7:45 am

Sunrise Symposium 1: Case Studies: Fantastic Failures and Sensational Successes in Heart Transplantation*

(Convention Hall)

Moderators: Maria Rosa Costanzo, MD, and John Wallwork, MBChB, FRCS

Sunrise Symposium 2: Case Studies: Fantastic Failures and Sensational Successes in Lung Transplantation

(Room 1001-1003)

Moderators: Jim Egan, MD, and Alec Patterson, MD

8:00 am-10:00 am

Plenary Session* (Convention Hall)

Moderators: Sharon Hunt, MD, and Jochum Prop, MD, PhD

Pioneers in Transplantation Lecture, Joel D. Cooper, MD, Washington University School of Medicine, St. Louis, MO

Invited Lecture: New LVADS and Artificial Heart Technology, O.H. Frazier, MD, Texas Heart Institute, Houston, TX.

Featured and Caves Candidate Abstracts

9:00 am (71) *Graft Failure After Heart Transplantation in Children: A Six Year Multi-Center Experience*, W.R. Morrow, D.C. Naftel, R.L. Caldwell, J.E. Harrell, K. Ainley, J.K. Kirklin and the Pediatric Heart Transplant Study (PHTS), University of Alabama, Birmingham, AL, University of Indiana, Indiana, and University of Arkansas, Little Rock, AR

9:15 am (72) *Origin of Vascular Smooth Muscle Cells in Chronic Rejection Related Vasculopathy: Donor Versus Recipient*, J-L. Hillebrands, B.v.d. Hurk, E. Popa, F. Klatter, P. Nieuwenhuis, J. Rozing, Departments Histology and Cell Biology, University of Groningen, Groningen, The Netherlands

9:30 am (73) *Partial Left Ventriculectomy: The First International Registry Report*, Society for Cardiac Volume Reduction, Isehara, Japan

9:45 am (74) *Polyurethane Augments IL-2 Production by Activated T Cells, Resulting in CD95-Dependent T Cell Apoptosis*, M. Schuster, J. Andersmit, A. Kocher, N. Schuster, E. Rose, M. Oz, N. Edwards, S. Itescu, Columbia University, New York, NY

10:00 am–10:30 am

Coffee Break/Visit Exhibits/View Posters (Event Hall 2)

10:30 am–Noon

Concurrent Session 10

Lung/Heart-Lung Transplantation 2: Outcome Measurements and Predictions* (Convention Hall)

Moderators: Ed Garrity, MD, and Walter Klepetko, MD

10:30 am (75) *Single Versus Bilateral Lung Transplantation for End-Stage Emphysema: Influence of Recipient Age on Survival*, D.M. Meyer, L.E. Bennett, R.J. Novick, J.D. Hosenpud, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; ISHLT/UNOS Registry, Richmond, VA; London Health Sciences Centre, London, Ontario, Canada; Medical College of Wisconsin, Milwaukee, WI

10:45 am (76) *Decreased Survival Associated With Size Mis-Matching in Lung Transplantation*, S. Park, B. Grubbs, D. Nguyen, K. Savik, M. King, M. Hertz, R. Bolman III, University of Minnesota, Minneapolis, MN

11:00 am (77) *Rate of Decline in Patients Following 10% Drop From Baseline FEV₁*, C. Chaparro, J. Maurer, C. Gutierrez, C. Chan, S. Keshavjee, M. Hutcheon, Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada

11:15 am (78) *Lung or Heart-Lung Transplantation for Eisenmenger's Syndrome: Analysis of the ISHLT/UNOS Joint Thoracic Registry*, T.K. Waddell, L.E. Bennett¹, R. Kennedy, T.R.J. Todd, S. Keshavjee, University of Toronto, Toronto, Ontario, Canada, and ¹UNOS, Richmond, VA

11:30 am (79) *Cystic Fibrosis Patients May Require Waiting Time Adjustment*, W.T. Vigneswaran, M.A. McCabe, S.M. Bhorade, M. Bakhos, T.J. Hinkamp, E.R. Garrity, Loyola University Medical Center, Maywood IL

11:45 am (80) *Bronchial Hyperreactivity Three Months After Lung Transplantation Predicts Early Death*, M.B. Stanbrook, C. Gutierrez, S. Keshavjee, M. Hutcheon, Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada

10:30 am–Noon

Concurrent Session 11

Mechanical and Circulatory Support 1: Biomaterials and Patient Interaction (Room 1001-1003)

Moderators: Paul Hendry, MD, and Takeshi Nakatani, MD, PhD

10:30 am (81) *Development of Anti-Major Histocompatibility Complex Class I or II Antibodies Following LVAD Implant: Effects on Subsequent Allograft Rejection and Survival*, F.D. Pagani, D.B. Dyke, S. Wright, C. Donaldson, G.M. Deeb, S.F. Bolling, R. Prager, R. Cody, K.D. Aaronson, University of Michigan, Ann Arbor, MI

10:45 am (82) *Use of Multisystem Monitoring and Multidrug Approach Results in a Low Level of CNS Thromboembolic Events in Patients on the Cardiowest Total Artificial Heart: A Single-Center Experience*, P.E. Nolan, F.A. Arabia, R.G. Smith, D. Arzouman, V. Paramesh, G.K. Sethi, S. Sharma, M. McCarthy, M.E. Banchy, J.G. Copeland, The University of Arizona, Tucson, AZ

11:00 am (83) *Cellular Evidence for Regression of Fibrosis and Hypertrophy Following Mechanical Circulatory Support*, G. Torre-Amione, B.A. Bruckner, S.J. Stetson, K.A. Youker, J.A. Farmer, D. Weilbaeher, B. Radovancevic, O.H. Frazier, G.P. Noon, Baylor College of Medicine and the Texas Heart Institute, Houston, TX

11:15 am (84) *Reduction of Embolic Complications in Left Ventricular Assist System (LVAS) Recipients: Impact of Inflow Conduit Design*, N. Ramasamy¹, D. Wheeldon¹, P. Jansen¹, H. Chen¹, J.S. Jassawalla¹, P.M. Portner^{1,2}, ¹Novacor Division, Cardiovascular Group, Baxter Healthcare Corporation, Oakland, and ²Stanford University Medical Center, Stanford, CA

11:30 am (85) *Myocardial Recovery in Patients With Prolonged Mechanical Left Ventricular Support*, M. Nishimura, S. Ohtake, Y. Sawa, N. Fukushima, G. Matsumiya, S. Taketani, K. Horiguchi, H. Matsuda, Osaka University, Suita, Osaka, Japan

11:45 am (86) *The Use of Tissue Engineering to Improve the Biocompatibility of the Left Ventricular Assist Device*, D. Rosenstrauch, T.S. Burden, O.H. Frazier, Texas Heart Institute, Houston, TX

10:30 am-Noon

Concurrent Session 12

Nursing and Social Sciences (Event Hall 1)

Moderators: Juntaro Ashikari, MS, and Katherine Hoercher, RN

10:30 am (87) *Predictors of Quality of Life in Patients at 1 Month After Left Ventricular Assist Device Implantation* K.L. Grady, P. Meyer, A. Mattea, M.R. Costanzo, W. Piccione, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; D. Dressler, St. Luke's Medical Center, Milwaukee, WI; S.M. Ormaza, University of Minnesota, Minneapolis, MN; C. White-Williams, University of Alabama, Birmingham, AL; S. Chillcott, Sharp Memorial Hospital, San Diego, CA; A. Kaan, St. Vincent's Hospital, Darlinghurst, Sydney, Australia; B. Todd, Temple University, Philadelphia, PA; A. Fu, University of Pennsylvania, Philadelphia, PA; A Klemme, Fairfax Hospital, Falls Church, VA

10:45 am (88) *A Comparison of Quality of Life From Pre-to Post Lung Transplant - A Pilot Study*, J.D. Manzetti, J.L. Vensak, T.M. Aquilino, M.A. Dew, J. Ristich, C.L. Wells, J.H. Dauber, A.T. Iacono, K.R. McCurry, B.P. Griffith, R.J. Keenan, University of Pittsburgh, Pittsburgh, PA

11:00 am (89) *Who Returns to Work 1 Year After Heart Transplantation*, C. White-Williams, A. Jalowiec, K. Grady, University of Alabama Medical Center, Birmingham, AL; Loyola University Medical Center, Maywood, IL; and Rush-Presbyterian-St. Lukes Medical Center, Chicago, IL

11:15 am (90) *Patient Self-Report vs Toxicology to Confirm Abstinence From Tobacco Products, Alcohol, or Illicit Drugs*, I.L. Paradis, W. Paris, D. Nelson, S. Kessinger, J. Tripp, J. Wood, C. Smith, D. Vanhooser, J. Chaffin, Nazih Zuhdi Transplantation Institute, Integriss Baptist Medical Center, Oklahoma City, OK

11:30 am (91) *Concern Regarding the Use of Orlistat (Xenical) For the Treatment of Obesity in Cardiac Transplant Recipients*, R. Camara, J.A. Kobashigawa, S. Lackey, J.M. Chuang, J.D. Moriguchi, N. Kawata, H. Laks, University of California, Los Angeles, CA

11:45 am (92) *Can We Treat Noncompliance and Decrease Graft Loss and Death?* J.F. Douglas, J. Slater, D.T. Hsu, J. Lamour, A. Burke, L.J. Addonizio, Babies and Children's Hospital, Columbia University, New York, NY

Noon-12:45 pm

Box Lunch Pick-up (Event Hall 2)

Noon-2:00pm

Visit Exhibits/View Posters (Event Hall 2)

12:15 pm-1:30 pm

Mid-Day Workshop 4: Psychosocial and Behavioral Issues in Transplantation (Room 1001-1003)

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

Sabina De Geest, RN, PhD, University of Basel, Basel, Switzerland

Jo Wray, PhD, Royal Brompton and Harefield NHS Trust, Harefield, UK

12:15 pm-1:30 pm

Mid-Day Workshop 5: Surgical Alternatives for Heart Failure: Anything But a Transplant (Event Hall 1)

Steve Bolling, MD, University of Michigan Hospitals, Ann Arbor, MI

Soichiro Kitamura, MD, National Cardiovascular Center, Osaka, Japan

Nicholas Smedira, MD, Cleveland Clinic Foundation, Cleveland, OH

12:30 pm-1:45 pm

Mid-Day Workshop 6: Core Curriculum: Clinical Significance of Basic Immune Testing* (Convention Hall)

Supported in part by an educational grant from the American Society of Histocompatibility and Immunogenetics

Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

Robert Bray, PhD, Emory University Hospital, Atlanta, GA

Nancy Reinsmoen, PhD, Duke University Medical Center, Durham, NC

12:15 pm-1:45 pm

Mini Oral Poster Presentation Session 2 (Room 1009)

Moderators: Alan H. Menkis, MD, and Gunther Laufer, MD

12:15 pm (93) *Effects of EP4 and LPD Solutions vs Euro-Collins Solution on Na⁺/K⁺-ATPase Activity in Alveolar Epithelial Cells*, S. Suzuki, K. Inoue, M. Sugita, T. Kondo, S. Fujimura, Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

12:21 pm (94) *Successful Orthotopic Cardiac Transplantation Following 24-Hr Preservation Using a Hypothermic Perfusion Apparatus in Canine Hearts*, H. Tsutsumi, K. Oshima, J. Mohara, I. Takeyoshi, M. Aizaki, M. Takumine, K. Matsumoto¹, Y. Morishita, Gunma University School of Medicine, Maebashi, and ¹Second Hospital of Nippon Medical School, Kawasaki, Japan

(95) WITHDRAWN

12:27 pm (96) *In-Situ-Protection-Catheter-Technique of Hearts for Transplantation*, A.M. Scheule¹, W. Beierlein¹, D. Jost¹, J. Haas¹, U. Vogel², S. Miller³, H.P. Wendel¹, G. Ziemer¹, Abteilung für Thorax, ¹Herz and Gefäßchirurgie, ²Institut für Pathologie, ³Abteilung für Diagnostische Radiologie, Universitätsklinikum Tübingen, Tübingen, Germany

12:33 pm (97) *Extended Tracheal Allotransplantation: Removal of Cartilage Rings of the Graft, Omentopexy and Immunosuppression: An Experimental Study*, H. Oizumi, T. Masaoka, T. Fujishima, Y. Naruke, S. Shiono, Y. Shimazaki, Yamagata University School of Medicine, Yamagata, Japan

12:39 pm (98) *Low Diagnostic Value of Dobutamine Stress Echocardiography for Noninvasive Assessment of Cardiac Allograft Vasculopathy in a Population With Low Incidence of Vasculopathy*, A.W. Chan, B. Munt, J.G. Webb, R.G. Carere, A.P. Ignaszewski, St. Paul's Hospital, Vancouver, British Columbia, Canada

12:45 pm (99) *Cellular Rejection and Rate of Progression of Transplant Vasculopathy: A 3 Year Serial Intravascular Ultrasound Study*, J. Jimenez, S.R. Kapadia, M.H. Yamani, L. Platt, R.E. Starling, J.B. Young, S.E. Nissen, E. Murat Tuzcu, The Cleveland Clinic Foundation, Cleveland, OH

12:51 pm (100) *Usefulness of Intracoronary Ultrasound in the Evaluation of Late Symptoms After Heart Transplantation*, J. Segovia, L.A. Pulpón, F. Alfonso, J. Goicolea, A. Fernández-Ortiz, R. Hernandez, C. Bañuelos, J. Escaned, C. Macaya, Clínica Puerta de Hierro and Hospital Universitario San Carlos, Madrid, Spain

12:57 pm (101) *Factors Affecting Proximal Coronary Artery Remodeling After Cardiac Transplantation* A.A. Bove, X.Y. Zhang, H. Valentine¹, B. Mellein², E.A. Mueller², H.J. Eisen, for the OLN 351 Core Study Group, Temple University, Philadelphia, PA; ¹Stanford University, Palo Alto, CA; and ²Novartis Pharma, Basel, Switzerland

1:03 pm (102) *Heart Transplant Coronary Artery Disease*, J. Wei, K.C. Lee, D.Y. Tung, C.Y. Chang, Y.C. Chuang, Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan

1:09 pm (103) *Molecular Markers of Apoptosis and Donor Heart Dysfunction*, N. Latif, E. Birks, P. Burton, N.R. Banner, M.H. Yacoub, Heart Science Centre, NHLI at Imperial College, Harefield Hospital, Harefield, United Kingdom

1:15 pm (104) *Egr-1 and BTEB-2 Expression in Cardiac Allografts*, Y. Wada¹, J. Suzuki², M. Kawauchi³, N. Watanabe², T. Zhang¹, K. Tsukioka¹, M. Endoh³, M. Kurabayashi⁵, R. Nagai⁴, S. Takamoto³, M. Isobe², J. Amano¹, ¹The Second Department of Surgery and ²The First Department of Internal Medicine, Shinshu University, Nagano; ³The Department of Thoracic Surgery and ⁴The Department of Cardiology, University of Tokyo, Tokyo; ⁵The Second Department of Internal Medicine, Gunma University, Gunma, Japan

1:21 pm (105) *Intra-Aortic Balloon Pumping in Children With Dilated Cardiomyopathy as Bridge to Transplantation*, R.E. Shaddy, L.L. Minich, L.Y. Tani, G.S. Orsmond, G.B. DiRusso, J.A. Hawkins, Departments of Pediatrics and Surgery, Primary Children's Medical Center and the University of Utah, Salt Lake City, UT

1:27 pm (106) *Lung Transplantation Offers a Survival Advantage to Children With End-Stage Pulmonary Hypertension*, D.M. Bush, P.S. Ro, T.L. Spray, N.D. Bridges, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA

1:33 pm (107) *Heart Transplantation in Children: A Fifteen-Year Experience at the Millennium*, J. Odum, H. Laks, A. Sadeghi, D. Drinkwater, C. Komanapalli, A. Galindo, J. Alejos, UCLA Medical Center, Los Angeles CA

2:00 pm-3:30 pm

Concurrent Session 13

Mechanical and Circulatory Support 2: Clinical Experience* (Convention Hall)

Moderators: Nicholas Smedira, MD, and George Wieselthaler, MD

2:00 pm (108) *Mid-Term Follow-Up of Out-of-Hospital (OOH) Left Ventricular Assist Device Patients*, A. El-Banayosy, O. Fey, P. Sarnowski, L. Arusoglu, G. Tenderich, K. Minami, R. Körfer, Department of Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany

2:15 pm (109) *Mechanical Circulatory Support for Advanced Heart Failure: Effect of Patient Selection on Success*, P. Jansen, D. Wheeldon, P. Portner, Baxter Cardiovascular Group, Novacor Division, Utrecht, The Netherlands

2:30 pm (110) *Assessment of Synchrony Relationships Between the Native Cardiac Cycle and the TCI Left Ventricular Assist Device*, S. Maybaum, A. Choudhri, H. Levin, D. Spierer, M. Oz, D. Mancini, Columbia University, New York, New York

2:45 pm (111) *Multicenter Experience With the Thoratec® Ventricular Assist Device (VAD) in Children and Adolescents*, O. Reinhartz¹, F.M. Keith¹, A. El-Banayosy², L.R. McBride³, R.C. Robbins⁴, J.G. Copeland⁵, D.J. Farrar⁶, ¹UCSF Medical Center, San Francisco, CA; ²Heart Center Bad Oeynhausen, Bad Oeynhausen, Germany; ³St. Louis University, St. Louis, MO; ⁴Stanford University, Palo Alto, CA; ⁵University of Arizona, Tucson, AZ; ⁶Thoratec Laboratories, Pleasanton, CA

3:00 pm (112) *ECMO to LVAD Bridge to Heart Transplant: Optimizing Survival and LVAD Resources*, F.D. Pagani, D.B. Dyke, S. Wright, C. Donaldson, S.F. Bolling, G.M. Deeb, R. Prager, F. Swaniker, R. Bartlett, M. Moscucci, R. Cody, K.D. Aaronson, University of Michigan, Ann Arbor, MI

3:15 pm (113) *Analysis of Preoperative Comorbid Factors Associated With Biventricular Assist Device and Total Artificial Heart: A Single Center Experience*, V.K. Mehta, J.G. Copeland, F.A. Arabia, R.G. Smith, M.E. Banchy, University of Arizona, Sarver Heart Center and University Medical Center, Tucson, AZ

2:00 pm-3:30 pm

Concurrent Session 14

Clinical Heart Transplantation 3: Infectious Complications (Room 1001-1003)

Moderators: Peter Bergin, MD, and Florian Wagner, MD

(114) WITHDRAWN

2:00 pm (276) *Chagas' Heart Disease is Associated with Better Survival After Heart Transplantation in Comparison with Ischemic and Idiopathic Etiologies: A Multicenter Study*, E.A. Bochi, A. Fiorelli, for the Transplantation Guidelines Group, Brazilian Society of Cardiology, Sao Paulo, Brazil

2:15 pm (115) *Ganciclovir Prophylaxis Alone is Equally Effective to a Combined Regimen of Acyclovir with Cytogam® (CMVig) in Preventing Cytomegaloviral Infection in Heart Transplant Recipients*, A. Beniaminovitz, E. Kurtz, B. Scully, D. Mancini, Columbia University, New York, NY

2:30 pm (116) *Preemptive Antiviral Therapy in Cytomegalovirus Negative Recipients of Hearts From CMV Positive Donors is Superior to Prophylaxis*, B. Radovancevic, R. Radovancevic, C. Thomas, M. LaRocco, S. Burgert, L. Gentry, O.H. Frazier, Texas Heart Institute and St. Luke's Episcopal Hospital, Houston, TX

2:45 pm (117) *Prophylaxis of CMV Disease in Mismatched Patients After Heart Transplantation Using Combined Antiviral and Immunoglobulin Therapy*, A.V. Wong, L.S.C. Czer, S.C. Jordan, C. Blanche, P. Nusser, D. Harasty, R.A. Mathiasen, M. Sandhu, A.Trento, Departments of Cardiothoracic Surgery and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

3:00 pm (118) *Seroconversion Following Transplantation of Hepatitis C Positive Donor Hearts is Associated With Increased Morbidity and Mortality*, P.A. Fedalen, R. Vattikuti, C.A. Fiser, J.P. Gaughan, D. Ramasamy, F.I. Goldman, S. Furukawa, H.J. Eisen, V. Jeevanandam, Temple University School of Medicine, Philadelphia, PA, and the University of Chicago, Chicago, IL

3:15 pm (119) *Hepatitis B Virus Infection in Heart Transplantation*, W.J. Ko, N.K. Chou, S.S. Wang, S.H. Chu, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan

2:00 pm–3:30 pm

Concurrent Session 15

Xenotransplantation: Are We Really Making any Progress? (Event Hall 1)

Moderators: Robert Michler, MD, and Robert Robbins, MD

2:00 pm (120) *Over One-Year Survival of Orthotopically Transplanted Monkey Hearts in Baboons: Immunosuppressive Strategy for Long-Term Survival*, H. Izutani, S.R. Gundry, M. Asano, O. Fagoaga, CW. Zuppan, L.L. Bailey, Loma Linda University Medical Center, Loma Linda, CA

2:15 pm *Invited Commentary*: John Wallwork, FRCS, Papworth Hospital, Cambridge, United Kingdom

2:22 pm (121) *Effect of Various Glycosyltransferases on the Swine Glycosphingolipids Bearing the Major Xenoantigen*, M. Koma, S. Miyagawa, Y. Ikeda, S. Koyota, A. Murase, K. Honke, S. Miyoshi, H. Matsuda, N. Taniguchi, R. Shirakura, Osaka University Graduate School of Medicine, and PROBRAIN, Osaka, Japan

2:37 pm (122) *Allosensitization Increases Human Anti-Pig Cellular Xenoreactivity*, S.H. Popma, A.M. Krasinskas, D. Kreisel, W.Y. Szeto, M. Kamoun, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

2:52 pm *Invited Commentary*, Silviu Itescu, MD, Columbia Presbyterian Medical Center, New York, NY

2:59 pm (123) *Twenty Days Survival After Orthotopic Xenotransplantation of HDAF-Transgenic Pig Hearts Into Baboons*, P. Brenner¹, M. Schmoeckel¹, H. Reichenspurner¹, C. Wimmer¹, V. Eder¹, A. Rucker¹, S. Uchita¹, M. Hinz¹, J. Müller-Höcker³, B. Meiser¹, C. Hammer², B. Reichart¹, ¹Department of Cardiac Surgery, ²Institute for Surgical Research, and ³Pathological Institute, University of Munich, Munich, Germany

3:15 pm (124) *Immunoabsorption Treatment of Hyperacute and Delayed Xenograft Rejection After Xenotransplantation of Landrace HDAF Transgenic Pig Hearts into Baboons*, P. Brenner¹, M. Schmoeckel¹, H. Reichenspurner¹, C. Wimmer¹, V. Eder¹, A. Rucker¹, T. Felbinger³, M. Hinz¹, S. Uchita¹, B. Meiser¹, C. Hammer², B. Reichart¹, ¹Department of Cardiac Surgery, ²Institute for Surgical Research, and ³Institute of Anesthesiology, University of Munich, Munich, Germany

3:30 pm-4:00 pm

Coffee Break/Visit Exhibits/View Posters (Event Hall 2)

4:00 pm-5:30 pm

Concurrent Session 16

Alternatives to Transplantation* (Convention Hall)

Moderators: Steve Bolling, MD, and Hitoshi Koyanagi, MD

4:00 pm (125) *Multivariate Analysis on Factors Affecting Results After Partial Left Ventriculectomy*, A.T. Kawaguchi, N. Takahashi, H. Ishibashi-Ueda, L.M. Linde, J. Bergsland, T.A. Salerno, S. Koide, R.J.V. Batista, Society for Cardiac Volume Reduction, Isehara, Kanagawa, Japan

4:15 pm (126) *Modulation of Functional Mitral Regurgitation and Mitral Valve Closure by Left Ventricular Pacing in Heart Failure Patients With Markedly Prolonged QRS Complex*, M. Goethals, M. Roba, I. Anguera, J. Champagne, M. Vanderheyden, P. Brugada, Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium

4:30 pm (127) *Device Based Left Ventricular Shape Change as a New Surgical Therapy for Heart Failure: A Pilot Study in a Pacing Induced Canine Cardiomyopathy Mode*, K. Fukamachi, P.M. McCarthy, M. Takagaki, Y. Ochiai, M. Al-Ahmadi, R. Dessoffy, J.B. Young, Cleveland Clinic Foundation, Cleveland, OH; C.J. Schweich, Jr., T.J. Mortier, M.R. Raffé, Myocor Inc, Plymouth, MN

4:45 pm (128) *Clinical and Hemodynamic Short Term Results With Passive Cardiomyoplasty*, W. Konertz, B. Rombeck, M. Zytowski, H. Hotz, H.N. Sabbah, C. Alferness, F. Kleber, Humboldt University Charite, and Unfallkrankenhaus Berlin, Berlin, Germany; Henry Ford Heart and Vascular Institute, Detroit, MI

5:00 pm (129) *Transplantation of Culture-Expanded, Cryopreserved Fetal Cardiomyocytes into Myocardial Scar Tissue - Prolonged Survival With Angiogenesis and Improved LV Function*, K.M.T. Chong, Z.P. Ding, S. Arulkumaran, L. Retnam, A. Bongso, Department of Cardiothoracic Surgery, National Heart Centre, Singapore and the National University of Singapore, Singapore

5:15 pm (130) *Creation of a Skeletal Myoblast Cell Line Overexpressing Connexin 43 as a Novel Strategy for Cell Transplantation to the Heart*, K. Suzuki, N.J. Brand, M.A. Kahn, A.O. Farrell, M.H. Yacoub, Heart Science Centre, Harefield Hospital, Middlesex, United Kingdom

4:00 pm-5:30 pm

Concurrent Session 17

Basic Science and Immunobiology 3: Cytokines (Room 1001-1003)

Moderators: Gregory Hirsch, MD, and Ryota Shirakura, MD

4:00 pm (131) *The TNF- α System After Heart Transplantation Measured by Quantitative Flow Cytometry, RT-PCR and Elisa*, I.C. van Riemdsdijk, C.C. Baan, E.H.M. Loonen, C.J. Knoop, A.H.M.M. Balk, A.P.W.M. Maat, W. Weimar, Departments of Internal Medicine, Cardiology and Thoracic Surgery, University Hospital, Rotterdam, The Netherlands

4:15 pm (132) *Failure to Downregulate Intragraft Cytokine mRNA Expression After Clinical Heart Transplantation Leads to a High Incidence of Rejection*, H.A. De Groot-Kruseman, C.C. Baan, E.H. Loonen, W.M. Mol, H.G. Neistes, A.P. Maat, A.H. Balk, W. Weimar, Department of Internal Medicine I, Diagnostic Institute of Molecular Biology and Thorax Centre, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands

4:30 pm (133) *Expression of Allograft Inflammatory Factor-1 (AIF-1) in Vascular Smooth Muscle Cells of Coronary Arteries and Endomyocardial Biopsies of Transplanted Human Hearts*, M.V. Autieri, S.E. Kelemen, C.J. Carbone, H.J. Eisen, Temple University School of Medicine, Philadelphia, PA

4:45 pm (134) *Expression of Allograft Inflammatory Factor-1 (AIF-1) is a Marker of Activated Human Vascular Smooth Muscle Cells and Arterial Injury*, M.V. Autieri, C. Carbone, A. Mu, H.J. Eisen, Temple University School of Medicine, Philadelphia, PA

5:00 pm (135) *CD4+ Helper Function is Delivered Via the Secretion of IFN- γ* , M.P. Fischbein, J. Yun, H. Laks, Y. Irie, M.C. Fishbein, M. Espejo, B. Bonavida, A. Ardehali, University of California, Los Angeles, CA

5:15 pm (136) *Modulation of Cytokine Profile in Situ by Localized Adenovirus-Mediated IL-10 Gene Therapy in Acute Cardiac Rejection*, G. Cui, H. Laks, Y-S Hong, M. Nonoyama, L. Sen, UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA

4:00 pm–5:30 pm

Concurrent Session 18

Pediatrics 1: Long Term Outcome of Pediatric Transplant Recipients (Event Hall 1)

Moderators: Robert Boucek, MD, and Francisco Parisi, MD

4:00 pm (137) *Growth and Pubertal Development Following Pediatric Heart Transplantation, A 13 Year Experience*, E. De Broux, C. Huot, S. Chartrand, S. Vobecky, C. Chartrand, Ste-Justine Hospital, Montreal, Quebec, Canada

4:15 pm (138) *Effect of Diltiazem on Graft Coronary Artery Disease (CAD) in Pediatric Heart Transplant (HTX) Recipients*, D. Bernstein, C. Chin, J. Miller, P. Gamberg, R. Robbins, B. Reitz, Departments of Pediatrics and Cardiothoracic Surgery, Stanford University, Stanford, CA

4:30 pm (139) *The Impact of Cytokine Gene Polymorphism on Pediatric Heart Allograft Outcome*, A. Zeevi, I. Hutchinson, V. Pravica, C. Perrey, C. Sturchio, C. Zahbrobsky, J. Martell, C. Bentlejewski, M. Ahmed, D. Griffith, G. Boyle, Y. Law, S. Miller, B. Griffith, S. Webber, University of Pittsburgh, Pittsburgh, PA, and Biological Sciences, University of Manchester, Manchester, United Kingdom

4:45 pm (140) *Risk Factors for Recurrent Rejection in Pediatric Heart Transplantation: A Multicenter Experience*, C. Chin, D.C. Naftel, T.P. Singh, E.D. Blume, H. Juikart, D. Bernstein, W.R. Morrow, and the Pediatric Heart Transplant Study Group (PHTS), University of Arkansas, Wayne State University, University of Alabama, Harvard University, and Stanford University, Palo Alto, CA

5:00 pm (141) *Airway Growth After Pediatric Lung Transplantation*, P.S. Ro, D.M. Bush, S.S. Kramer, S. Mahboubi, T.L. Spray, N.D. Bridges, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA

5:15 pm (142) *Two Year Prospective Assessment of EBV Viral Load in 60 Long Term Pediatric Heart Transplanted Patients*, R. Fiocchi, L. Iamele, C. Mammana, A. Gamba, P. Ferrazzi, Cardiac Surgery Department, ORRR, of Bergamo, Italy

5:30 pm–6:30 pm

Moderated Poster Session 2/Wine and Cheese Reception (Event Hall 2)

(see end of program for list of poster titles)

6:30 pm–7:30 pm

Poster Session 2 Tear Down

7:30 pm–10:00 pm

President's Gala Reception (Korin Room, Rihga Royal Hotel)

Saturday April 8, 2000

6:30 am–Noon

Registration (Main Foyer)

6:30 am–8:00 am

Morning Coffee/Continental Breakfast (Event Hall 2)

6:30 am–11:30 am

Exhibits Open (Event Hall 2)

6:45 am-7:45 am

Sunrise Symposium 3: VADS: Which Pump for Which Patient?* (Convention Hall)

Aly El-Banayosy, MD, Herzzentrum NRW, Bad Oeynhausen, Germany

Mehmet C. Oz, MD, Columbia Presbyterian Medical Center, New York, NY

Sunrise Symposium 4: The Millenium Bug: Hepatitis (B & C) in Thoracic Organ Transplantation (Room 1001-1003)

Ed Gane, MD, Auckland Hospital, Auckland, New Zealand

G.W. McCaughan, MD, AW Morrow Gastroenterology and Liver Centre, University of Sydney, Sydney, Australia

8:00 am-10:00 am

Plenary Session* (Convention Hall)

Moderators: William Baumgartner, MD, and Anne Keogh, MBBS, MD

Pioneers in Transplantation Lecture, Christiaan Barnard, MD, Cape Town, South Africa

Featured and Caves Candidate Abstracts

8:30 am (143) *Targeting the Angiotensin System in Post-Transplant Airway Obliteration: The Antifibrotic Effect of ACE Inhibition*, A.A. MacLean, M. Liu, S. Fischer, M. Suga, S. Keshavjee, Thoracic Surgery Research Laboratory, The Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

8:45 am (144) *Mycophenolate Mofetil Compared to Azathioprine Improves Survival in Patients Surviving the Initial Cardiac Transplant Hospitalization: An Analysis of the Joint ISHLT/UNOS Thoracic Registry*, J.D. Hosenpud, L.E. Bennett, The Medical College of Wisconsin, Milwaukee, WI, and the United Network for Organ Sharing, Richmond, VA

9:00 am (145) *Heat Shock Protein 70 (HSP70) Gene Transfection Protects Donor Rat Hearts Against Ischemia-Reperfusion Injury*, J. Jayakumar, K. Suzuki, R.T. Smolenski, M. Khan, A. Farrell, N. Latif, O. Raisky, K. Morrison, H. Abunasra, A. Chester, M. Amrani, M.H. Yacoub, National Heart and Lung Institute, Harefield Hospital, Middlesex, United Kingdom

9:15 am (146) *Survival in Cystic Fibrosis and Optimal Timing of Lung Transplantation*, T.G. Liou¹, F.R. Adler², B.C. Cahill¹, S. FitzSimmons³, J.R. Hibbs⁴, B.C. Marshall¹, ¹International Medicine, ²Math, and Biology, University of Utah, Salt Lake City, UT; ³Cystic Fibrosis Foundation, Bethesda, MD; ⁴New York State Department of Microbiology, Albany, NY

9:30 am (147) *Signaling Through CD40 Can Replace the Requirements of CD4⁺ Lymphocytes in Cardiac Allograft Vasculopathy*, M.P. Fischbein, J. Yun, H. Laks, Y. Irie, M.C. Fishbein, M. Espejo, B. Bonavida, A. Ardehali, University of California, Los Angeles, CA

9:45 am (148) *Porcine Endogenous Retrovirus is not Transmitted to Baboons Following Transgenic Pig Heart Transplantation and Prolonged Immunosuppression*, C.G.A. McGregor, J.R. Hibbs, D.H. Persing, Mayo Clinic, Rochester, MN

10:00 am-10:30 am

Coffee Break/Visit Exhibits (Event Hall 2)

10:30 am-Noon

Concurrent Session 19

Clinical Heart Failure 2: Use of Beta Blockers in Advanced Heart Failure* (Convention Hall)

Moderators: Masatsugu Hori, MD and Mitchell Saltzberg, MD

10:30 am (149) *Experience With β -Blocker Therapy in Patients With Advanced Heart Failure Evaluated for HTX* R. Berger, B. Frey, M. Hulsmann, B. Stanek, R. Pacher, University of Vienna, Vienna, Austria

10:45 am (150) *Tolerability of Carvedilol in Patients With Asthma or Chronic Obstructive Airway Disease*, E. Kotlyar, A.M. Keogh, P.S. Macdonald, R.H. Arnold, P.R. Hill, St. Vincent's Hospital, Sydney, Australia

11:00 am (151) *Can Beta Blockers be Safely Titrated in Patients With Abnormal Pulmonary Function Tests?*, C.E. Lawless, K. Malinowsak, G.M. Mullen, J.C. Mendez, B.A. Pisani, Heart Failure/Heart Transplant Program, Loyola University Medical Center, Mayood, IL

11:15 am (152) *Reverse Left Ventricular Remodeling in Response to Carvedilol Occurs Independently of the Baseline Heart Rate*, E. Kotlyar, R.H. Arnold, A.M. Keogh, P.S. Macdonald, St. Vincent's Hospital, Sydney, Australia

11:30 am (153) *Comparison Between Ischemic and Non-Ischemic Heart Disease in Carvedilol Therapy for Chronic Heart Failure*, Y. Endo, N. Matsuda, K. Imamura, K. Kajimoto, H. Ikegami, T. Shiga, M. Kawana, H. Kasanuki, The Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan

11:45 am (154) *Optimisation of Left Ventricular Function With Carvedilol Prior to High Risk Cardiac Surgery*, E. Kotlyar, P.M. Spratt, M.K. Wilson, R.H. Arnold, D. McCaffrey, A.M. Keogh, P.S. Macdonald, St. Vincent's Hospital, Sydney, Australia

10:30 am-Noon

Concurrent Session 20

Immunosuppression 2: Experimental and Animal (Room 1001-1003)

Moderators: Dale Renlund, MD, and Manfred Hummel, MD, PhD

10:30 am (155) *Long Term Treatment of Cyclosporine in a Rat Heart Transplant Model Increases the Intra-Renal Expression of Fibrogenic Molecules and Produces Intra-Renal Fibrosis*, J.D. Hosenpud, A.K. Khanna, J.S. Hosenpud, T.A. Boyle, H.R. Hensler, M.S. Plummer, The Medical College of Wisconsin, Milwaukee, WI

10:45 am (156) *SDZ RAD Plus Cyclosporine Blocks Transplant Atherosclerosis in Inbred Zucker Rats*, H.A. Valantine, Stanford University, Stanford, CA

11:00 am (157) *FR167653, an Inhibitor of TNF- α and IL-1 Production, Attenuates Ischemia and Reperfusion Injury of the Rat Lung Through P38 Mitogen Activated Protein Kinase Signal Pathway*, Y. Kawashima, I. Takeyoshi, Y. Ohtani, Y. Koibuchi, D. Yoshinari, K. Matsumoto¹, Y. Morishita, Gunma University School of Medicine, Maebashi, and ¹Nippon Medical School, Kawasaki, Japan

11:15 am (158) *Cyclosporin A Inhibits the Migration of Vascular Smooth Muscle Cells Into the Neointima of Arteries in a Cardiac Transplant Model. A Comparative Study with CSA and FK-506*, M. Richter, K. Kafchitas, H. Richter, Experimental Heart Transplant Group Frankfurt, University of Frankfurt, Frankfurt, Germany

11:30 am (159) *Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex Vivo E2F Decoy Transfection by HVJ-Ave-Liposome Method in Non-Human Primates*, M. Kawachi, J. Suzuki¹, R. Morishita², Y. Kaneda², S. Takamoto³, M. Isobe², JR Tokyo General Hospital, Tokyo, ¹Shinshu University, Nagano, ²Osaka University, Suita, and ³University of Tokyo, Tokyo, Japan

11:45 am (160) *Effectiveness of Treatment With Anti-CD25 MAB on Reduction of Immunologic Risk Factors for High-Grade Cardiac Allograft Rejection Depends on Donor/Recipient HLA-DR Matching*, K. Lietz, A. Beniaminovitz, E. Burke, M. Donovan, N. Suci-Foca, N. Edwards, D. Mancini, S. Itescu, Columbia University, New York, NY

10:30 am-Noon

Concurrent Session 21

Donor Management, Preservation, and Organ Distribution 2: Clinical (Event Hall 1)

Moderators: Shu Hsu Chu, MD, and Valluvan Jeevanandam, MD

10:30 am (161) *Use of Donor Lungs With Elevated Interleukin-8 (IL-8) Levels is Associated With Primary Graft Failure Following Human Lung Transplantation*, A.J. Fisher¹, S.C. Donnelly², N. Hirani², C. Haslett², R.M. Strieter³, J.H. Dark¹, P.A. Corris¹, ¹Cardiopulmonary Transplant Unit, Freeman Hospital and University of Newcastle upon Tyne, Newcastle Upon Tyne, United Kingdom; ²Rayne Laboratory, University of Edinburgh, Edinburgh, Scotland; ³Internal Medicine, University of Michigan, Ann Arbor, MI

10:45 am (162) *Temporal Changes in Donor Left Ventricular Function: Results of Serial Echocardiography*

J.G. Zaroff, L.L. Solinger, W.D. Babcock, University of California and the California Transplant Donor Network, San Francisco, CA

11:00 am (163) *Redefining the Marginal Donor Heart: Multivariate Analysis of Donor Dependent Factors for Early Graft Failure*, A.C. Anyanwu, C.A. Rogers, C. Jones, A.J. Murday and the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

11:15 am (164) *The Use of Marginal Donor Hearts*, D. Marelli, H. Laks, D. Fazio, A. Sadeghi, A. Ardehali, J. Moriguchi, E. Houston, M. Talamo, F. Esmailian, A. Hage, M. Hamilton, G. Fonarow, N. Kawata, J. Kobashigawa, University of California, Los Angeles, CA

11:30 am (165) *A Comparison of Celsior to Standard Cardiac Preservation Solutions for Cardiac Transplantation With High-Risk Donors*, J.D. Vega¹, E.D. Staples², D.C. McGiffin³, J.C. Stringham⁴ for the North American Celsior Study Group, ¹Emory University, Atlanta, GA, ²University of Florida, Gainesville, FL, ³University of Alabama, Birmingham, AL, and ⁴University of Utah, Salt Lake City, UT

11:45 am (166) *Could Liposome-DNA Complexes Encoding ecNOS be Delivered With Cold Cardioplegia to Transfect Donor Organs?* A. Iwata, Y. Nitta, M. Chen, M.D. Allen, Division of Cardiothoracic Surgery, University of Washington, Seattle, WA

11:30 am–5:00 pm
Exhibit Hall Tear Down (Event Hall 2)

Noon–12:30 pm
Annual Business Meeting (Members only) (Convention Hall)

12:15 pm-1:00 pm
Box Lunch Pick-up (Main Foyer)

12:45 pm-1:45 pm
Mid-Day Workshop 7: Core Curriculum: Review of Histologic Slides of Rejection: You Make the Call*
(Convention Hall)
Gerald Berry, MD, Stanford University, Palo Alto, CA

12:30 pm-2:00 pm
ISHLT Scientific Council Meetings:

Heart Failure and Transplant Medicine Council Meeting (Room 1008)
Nursing and Social Sciences Council Meeting Room (Room 1004)
Pathology and Basic Science Council Meeting (Room 1005)
Pediatric Transplantation Council Meeting (Room 1006)
Pulmonary Transplantation Council Meeting (Room 1007)
Ventricular Assist Devices/Total Artificial Hearts Council Meeting (Event Hall 1)

12:30 pm-2:00 pm
Mini Oral Poster Presentation Session 3 (Room 1009)
Moderators: Shigefumi Fujimura, MD, and Leslie W. Miller, MD

12:30 pm (167) *Early and Late Results of Domino Heart Transplantation*, A. Anyanwu, N. Banner, R. Radley Smith, A. Khaghani, M. Yacoub, Harefield Hospital, Uxbridge, Middlesex, United Kingdom

12:36 pm (168) *Multidisciplinary Study on Reinnervation After Heart Transplantation*, J.C. Gallego-Page, J. Segovia, L.A. Pulpón, C. Salas, C. Cristóbal, M. Alonso, A. Bautista, I. Antorena, E. Castedo, J. Ortiz-Berrocal, Clínica Puerta Hierro, Madrid, Spain

12:42 pm (169) *Hypotension, Acidosis, and Vasodilatation (HAV) Syndrome Post Heart Transplant: Prognostic Variables and Outcomes*, J. Chemmalakuzhy, M.R. Costanzo, P. Meyer, W. Piccione, W. Kao, E. Winkel, M. Saltzger, A. Heroux, J. Parrillo, Rush Medical College, Chicago, IL

12:48 pm (170) *Factors Predicting Survival Beyond 10 Years Following Heart Transplantation*, B. Radovancevic, C. Konuralp, R. Radovancevic, W. Vaughn, C. Thomas, M. Zagga, R. Delgado, O.H. Frazier, Texas Heart Institute/St. Luke's Episcopal Hospital, Houston, TX

12:54 pm (171) *Polymeric Biomaterials Induce T Cell Apoptosis and Defects in Cellular Immunity Via Increased Cellular Levels of NFAT and CD95 Ligand*, J. Ankersmit, M. Hoffman, A. Kocher, E. Wolner, E. Rose, N. Edwards, M. Oz, S. Itescu, Columbia University, New York, NY

1:00 pm (172) *Improvement in Quality of Life From Before to After Left Ventricular Assist Device Implantation*, K.L. Grady, A.M. Mattea, P. Meyer, M.R. Costanzo, W. Piccione, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; S.M. Ormaza, University of Minnesota, Minneapolis, MN; A. Kaan, St. Vincent's Hospital, Darlinghurst, Sydney, Australia; S. Chillcott, Sharp Memorial Hospital, San Diego, CA; A. Klemme, Fairfax Hospital, Falls Church, VA

1:06 pm (173) *Transplantation: A Definitive Therapy for Assist Device Infection and Septicemia*, A.S. Stewart, M.L. O'Hara, A. Pochettino, B.R. Rosengard, D. DeNofrio, E. Loh, M.A. Acker, Department of Surgery, Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

1:12 pm (174) *Volume Reduction Surgery Returns Cardiac Function to Baseline in a Chronic Model of Left Ventricular Dysfunction*, J.J. Pilla¹, S.V. Pusca¹, D.J. Brockman², M. Beal², F. Bowen¹, T.A. Plappert¹, M. St. John Sutton¹, M.A. Acker¹, ¹University of Pennsylvania School of Medicine, and ²Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA

1:18 pm (175) *Gene Expression After HVJ-Liposome Mediated Transfection Into the Lung. A Novel Approach in Lung Transplantation*, K. Omori, S. Takeda, Y. Sakamaki, S. Nakane, M. Minami, Y. Sawa, S. Miyoshi, H. Matsuda, 1st Department of Surgery, Osaka University Medical School, Osaka, Japan

1:24 pm (176) *The Impact of Hepatitis C Infection on Thoracic Organ Transplantation at Stanford*, O.A. Akindipe, H. Luikart, R. Doyle, F. Kwakwa¹, J. Theodore, Stanford University, Stanford, CA, and ¹American College of Surgeons, Chicago, IL

1:30 pm (177) *Impact of Donor Gram Stain on Recipient Outcome Following Lung Transplantation*, D. Weill, C.A. Goheen, W.D. Ogden, M.J. Magee, Medical City Hospital, Dallas, TX

1:36 pm (178) *Early Detection of CMV Disease by the Hybrid Capture Assay in Lung Transplantation*, C. Sandesara, S.M. Bhorade, E. Garrity, L. Norwick, M.A. McCabe, A. Husain, V. Yeldandi, Loyola University Medical Center, Maywood, IL

1:42 pm (179) *Load-Dependent Upregulation of the Atrial Interleukin-6 Gene in Advanced Human Heart Failure*, M.C. Deng, G. Plenz^{1,2,3}, Z.F. Song¹, H.H. Scheld¹, D. Borgmeier, H.A. Baba⁴, M. Erren⁵, H. Robenek³, Departments of ¹Cardiothoracic Surgery, Cardiology and ²Angiology, Institute of Arteriosclerosis Research, Division of ³Cell Biology and Ultrastructural Research, ⁴Gerhard-Domagk-Institute of Pathology, and ⁵Central Laboratory, Muenster University Hospital, Muenster, Germany

1:48 pm (180) *The Skeletal Muscle Intrinsic Mitochondrial Oxidative Capacity is Preserved in Severe Heart Failure*, E. Epailly, H. Sanchez, B. Mettauer, J. Zoll, E. Lambert, F. Ribeira, V. Veksler, A.X. Bigard, J. Lonsdorfer, R. Ventura-Clapier, Faculty of Medicine, Strasbourg, France

1:54 pm (181) *Down-Regulation of the α -Myosin Heavy Chain (MHC) Gene Expression During Heart Failure is Controlled by a Repressor Binding to a Purine-Rich Negative Regulatory Element*, M.P. Gupta, M. Gupta, M.R. Bristow, D. Jayakar, V. Jeevanandam, Department of Surgery, University of Chicago, Chicago, IL; Hope Children's Hospital, Oak Lawn, IL; and Department of Cardiology, University of Colorado, Denver, CO

2:00 pm-3:30 pm

Concurrent Session 22

Clinical Heart Transplantation 4: Allograft Vasculopathy* (Convention Hall)

Moderators: Alain Heroux, MD, and James B. Young, MD

2:00 pm (182) *Serum Soluble Intercellular Adhesion Molecule-1 and Risk Assessment of Transplant Coronary Artery Disease or Cardiac Graft Failure*, C.A. Labarrere, D.R. Nelson, S.J. Miller, D.E. Pitts, P.C. Kirlin, H.G. Halbrook, Methodist Research Institute, Clarian Health, Indianapolis, IN, and Cleveland Clinic Foundation, Cleveland, OH

2:15 pm (183) *Heart Transplant Recipients With Normal Coronary Angiograms: Is Intravascular Ultrasound Really Necessary?*, V. Klauss, K. Pethig¹, H. Kalies, E. Pichlmayer, B. Heublein¹, J. Rieber, C.H. Spes, B. Reichart, U. Siebert, A. Haverich¹, H. Mudra, K. Theisen, Department of Cardiology, Klinikum Innenstadt, University of Munich, Munich, and ¹Hannover Medical School, Hannover, Germany

2:30 pm (184) *Low Incidence and Severity of Transplant Coronary Artery Disease After Domino Heart Transplantation*, A. Anyanwu, N. Banner, A. Mitchell, A. Khaghani, M. Yacoub, Harefield Hospital, Uxbridge, Middlesex, United Kingdom

2:45 pm (185) *Cardiac-Specific Troponin I and Development of Coronary Artery Disease in Heart Transplant Recipients*, C.A. Labarrere, D.R. Nelson, C.J. Cox, D.E. Pitts, P.C. Kirlin, H.G. Halbrook, Methodist Research Institute, Clarian Health, Indianapolis, IN, and Cleveland Clinic Foundation, Cleveland, OH

3:00 pm (186) *Development of Circulating IgG Class I Antibodies is Associated With Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) After Heart Transplant*, J.A. Kobashigawa, S. Takemoto, L. Wener, J. Tobis, R. Lee, N. Kumar, J.M. Chuang, J.D. Moriguchi, N. Kawata, H. Laks, University of California, Los Angeles, CA

3:15 pm (187) *A Randomized Study of Efficacy and Safety of Pravastatin vs Atorvastatin in Heart Transplant Patients*, V. Carinci, G. Magnani, C. Magelli, L. Potena, A. Lombardi, L. Bacchi Reggiani, A. Branzi, Institute of Cardiovascular Disease, University of Bologna, Bologna, Italy

2:00 pm-3:30 pm

Concurrent Session 23

Lung/Heart-Lung Transplantation 3: Evolving Drug Therapies in Lung Transplantation (Room 1001-1003)

Moderators: Hermann Reichenspurner, MD, and Larry L. Schulman, MD

2:00 pm (188) *Preliminary Results of an International Randomised Multi-Centre Study of Mycophenolate Mofetil (MMf) vs Azathioprine (AZA) in Lung Transplantation*, K.D. McNeil, A. Glanville, P. Corris, T. Wahlers on behalf of the Mycophenolate Mofetil Lung Transplantation Study Group

2:15 pm (189) *Pharmacokinetics of RAD001 (RAD) in Stable Lung Transplant Patients With and Without Cystic Fibrosis (CF)*, R.L. Doyle¹, R.E. Morris¹, M.I. Hertz², J.M. Dunitz², J.E. Loyd³, A.A. Stecenko³, D. Tudor⁴, HT. Smith⁴, R.L. Wong⁴, K. Chappell⁴, J.M. Kovarik⁵, ¹Stanford University School of Medicine, Stanford, CA; ²University of Minnesota, Minneapolis, MN; ³Vanderbilt University, Nashville, TN; and ⁴Novartis Pharmaceuticals, East Hanover, NJ and ⁵Basel, Switzerland

2:30 pm (190) *Quantitative Analysis of MV PCR and Antigenemia are Complementary in Predicting Development of SMV Disease and Response to Therapy Post Transplant*, E. Gabbay, J. Flexman, R. Tarala, I. Kay, S. Palladino, R. Larbalestier, G. O'Driscoll, Cardiopulmonary Transplant Unit, Royal Perth Hospital, Perth, Australia

2:45 pm (191) *Impact of Oral Ganciclovir Prophylaxis in Lung Transplantation*, K. Perreas, L.D. Sharples, T. Wreghitt, C. Milano, K. Buchan, K. McNeil, J. Wallwork, Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom

3:00 pm (192) *Daclizumab, an Anti-Interleukin Receptor Antibody, May Decrease the Acute Rejection in Lung Transplant Patients*, J. Villalueva, S.M. Bhorade, M.A. McCabe, A. Husain, W. Vigneswaran, E.R. Garrity, Loyola University Medical Center, Maywood, IL

3:15 pm (193) *Pre-Plus Post Transplant Bisphosphonate Therapy Preserves Bone Mineral Density and Reduces Symptomatic Fracture After Lung Transplantation*, B.C. Cahill^{1,2}, M. O'Rourke², S.T. Parker², J.C. Stringham^{2,3}, S.V. Karwande^{2,3}, T. Knecht¹, ¹Internal Medicine, ²Lung Transplant Program, and ³CT Surgery, University of Utah, Salt Lake City, UT

2:00 pm-3:30 pm

Concurrent Session 24

Pediatrics 2: Perioperative Techniques and Modalities to Treat Pediatric Transplant Recipients (Event Hall 1)

Moderators: Nancy Bridges, MD, and Dominique Metras, MD

2:00 pm (194) *Series of ABO Incompatible Heart Transplants in Infants*, L.J. West, L.B. Benson, J.G. Coles, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

2:15 pm (195) *Positive Retrospective Crossmatch After Pediatric Heart Transplantation. Should We Worry?*, K.R. Kanter, A.M. Berg, R.A. Bray, R.N. Vincent, C.L. D'Amico, J.E. Holcomb, J.D. Vega, Emory University School of Medicine, Atlanta, GA

2:30 pm (196) *Utility of Extracorporeal Membrane Oxygenation for Early Donor Graft Failure Following Heart Transplantation in Infancy*, M.B. Mitchell, D.N. Campbell, M.R. Bielefeld, T.E. Doremus, The Children's Hospital, Denver, Colorado

2:45 pm (197) *ECMO for Myocardial Salvage in Children*, A.M. Sadeghi, H. Laks, J. Odum, J. Atkinson, D. Marelli, U. Mehta, UCLA Medical Center, Department of Surgery, Los Angeles, CA

3:00 pm (198) *Bronchiolitis Obliterans is not the Primary Cause of Death in Pediatric Living Donor Lobar Lung Transplant Recipients*, M.S. Wood, E.F. MacLaughlin, M.V. Horn, J.R. Szmuszkovicz, V.A. Starnes, Cardiothoracic Transplant Team, Divisions of Pediatric Pulmonology and Cardiology, Departments of Pediatrics and Cardiothoracic Surgery, Children's Hospital and USC School of Medicine, Los Angeles, CA

3:15 pm (199) *Induction Immunotherapy in Pediatric Heart Transplantation: Influence of Serum Mycophenolate Level Monitoring*, M.M. Boucek, D.D. Ivy, B. Pietra, E.M. Shaffer, H.M. Sondheimer, T.E. Doremus, D.N. Campbell, University of Colorado, The Children's Hospital, Denver, CO

3:30 pm-4:00 pm

Coffee Break (Foyer in front of Room 1001-1003))

4:00 pm-5:45 pm

Closing Plenary Session* (Convention Hall)

Moderators: Mark Barr, MD and Jon Kobashigawa, MD

4:00 pm *Invited Presentation: White Paper on Xenotransplantation*, David K.C. Cooper, MD, PhD, FRCS, Massachusetts General Hospital, Boston, MA

4:15 pm *Invited Lecture: Vascular Biology*, Marlene Rabinovitch, MD, Hospital for Sick Children, Toronto, Ontario, Canada

4:45 pm *Debate: Cyclosporine versus Tacrolimus in Thoracic Organ Transplantation: Which is Better?*

Pro Cyclosporine: Marshall Hertz, MD, University of Minnesota, Minneapolis, MN

Pro Tacrolimus: Bruno Meiser, MD, Grosshadern Medical Center, Munich, Germany

5:15 pm *Debate: Advanced Medical Therapy Renders Heart Transplantation Obsolete for the Ambulatory End-Stage Heart Failure Patient*

Pro: Lynne W. Stevenson, MD, Brigham and Women's Hospital, Boston, MA

Con: Jack Copeland, MD, University of Arizona Health Science Center, Tucson, AZ

5:45 pm-7:00 pm

ISHLT Board of Directors Meeting (Sapphire Room, Rihga Royal Hotel)

MODERATED POSTERS

SESSION 1

Thursday, April 6, 2000

5:30 pm-6:30 pm

(Session 1 Moderated Posters will be on display in Event Hall 2 from 10:00 am -6:30 pm on Thursday, April 6. Moderated Poster Session 1 authors will be available to answer questions about their posters during the wine and cheese reception from 5:30 pm - 6:30 pm on Thursday, April 6.)

Moderator: Lori West, MD, PhD

(200) *The Changing Presentation of Coronary Artery Disease (TCAD) in the Pediatric Heart Transplant Population*, Y.M. Law, G.J. Boyle, S.A. Miller, F. Pigula, S.A. Webber, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA

(201) *Impact of Overseas Transfer on Cost and Outcome for Japanese Pediatric Heart Transplant (PHTx) Recipients (Rps)*, K. Bando, S. Nunoda, J.W. Brown, M.W. Turrentine, T.G. Sharp, K. Yagihara, S. Kitamura, National Cardiovascular Center, Osaka, and Tokyo Women's Medical College, Tokyo, Japan; and Indiana University, Indianapolis, IN

(202) *Use of OKT3 for Acute Myocarditis in Infants and Children*, A. Galindo, J.C. Alejos, B. George, C. Burch, D. Marelli¹, A. Sadeghi¹, H. Laks¹, Division of Pediatric Cardiology, ¹Cardiothoracic Surgery, UCLA School of Medicine, Los Angeles, CA

(203) *Homograft Use Prior to Heart Transplant Does Not Increase Panel Reactive Antibodies or the Incidence of Rejection in Pediatric Heart Transplantation*, R.S. Fortuna, S.R. Gundry, A.J. Razzouk, M.M. del Rio, L.L. Bailey, Loma Linda Pediatric Heart Transplant Group, Loma Linda University, Loma Linda, CA

(204) *Outcome of Children Surviving 10 Years or More After Heart Transplantation (HT)*, J. LeBidois, D. Tamisier, P. Vouhe, P. Niaudet, D. Sidi, J. Kachaner, Hopital Necker Enfants Malades, Paris, France

(205) *Successful Treatment of Repeated Mild to Moderate Rejection With Mycophenolate Mofetil (MMF) After Heart Transplantation (HTx) is Mediated by a Reduction of Interleukin 2-Receptor (IL2-R) Positive T-Cells*, A. Rahmel^{1,2}, J. Gummert², N. Doll², G. Schuler¹, F.W. Mohr², ¹Department of Cardiology and ²Department of Cardiac Surgery, University of Leipzig-Heart Center, Leipzig, Germany

(206) *Mycophenolate Mofetil Improves Early Steroid Withdrawal in Orthotopic Heart Transplant Recipients*, S.S. Desai, D. DeNofrio, A. Kao, T.A. Frank, M.A. Acker, E. Loh, University of Pennsylvania, Philadelphia, PA

(207) *Tacrolimus Monotherapy After Cardiac Transplantation: Seven-Year Experience*. D.A. Baran, S. Kushwaha, R. Correa, M. Courtney, S.L. Lansman, A.L. Gass, Mount Sinai School of Medicine, New York, NY

Moderator: Joseph Rogers, MD

(208) *Heart Retransplantation: Results Can Be Superior to Primary Transplantation*, J.V. Conte, R. Scartozzi, M. Borja, E. Kasper, J. Hare, I. Wittstein, J.M. Redmond, D.E. Cameron, R.S. Stuart, K. Baughman, W.A. Baumgartner, Johns Hopkins Hospital, Baltimore, MD

(209) *What is the Concordance of Causes of Death in Multi-Center Heart Transplant Registries?* C.E. Lawless, K. Malinowska, L.K. Dusek, A.P. Broussard, G.M. Mullen, J.C. Mendez, B.A. Pisani, Loyola University Health Systems, Heart Failure/Heart Transplant Program, Maywood, IL

(210) *Improving Outcome of Cardiac Transplantation: ISO-Risk Decision Making*, J.M.J. DeMeester, J.M.A. Smits, E. Rutgrink, G.G. Persijn, A. Haverich, Eurotransplant International Foundation, Leiden, The Netherlands

(211) *A Pilot Study of L-Arginine for Renal Insufficiency in Heart Transplant Recipients*, J.D. Moriguchi, P. Bueno, J.A. Kobashigawa, J.M. Chuang, S. Lackey, R. Camara, N. Kawata, H. Laks, University of California, Los Angeles, CA

(212) *Effects of Mycophenolate Mofetil and Low-Dose Cyclosporine on Renal Function of Heart Transplant Recipients*, I. Aleksic, M.M. Baryalei, B. Schorn, J. Weisser¹, B. Pieske¹, H. Sirbu, T. Busch, H. Dalichau, Departments of Thoracic and Cardiovascular Surgery and Cardiology¹, Georg-August-University, Göttingen, Germany

(213) *Exercise Induced Increase in Circulating Adrenomedullin is Related to Mean Blood Pressure in Heart Transplant Recipient*, B. Geny, F. Piquard, E. Lampert, A. Charlous, B. Mettauer, S. Popescu, J. Lonsdorfer, Université Louis Pasteur, Strasbourg, France

(214) *Is Aerobic Capacity at One-Year Post-Heart Transplantation Associated With Long Term Survival?*, P.B. Rosenberg, P.A. Kaiser, R.R. Baliga, M.A. Solomon, M.H. Drazner, L.A. Hynan, W.S. Ring, C.W. Yancy, UT Southwestern Medical Center/St. Paul Medical Center, Dallas, TX

(215) *The Effects of Diltiazem on Post Cardiac Transplant Chronotropic Response and Exercise Capacity*, A. Kao¹, A.I. Kelleher², D.M. Kinzey², R.A. Schuff², G.J. Sexton², ¹University of Pennsylvania, Philadelphia, PA, and ²Oregon Health Sciences University, Portland, OR

Moderator: Mario Deng, MD

(216) *Relationship Between Severity of Tricuspid Regurgitation and Clinical Outcome After Heart Transplantation*, M.I. Burgess¹, T. Aziz², A. Bhattacharya¹, A.N. Rahman², A.K. Deiraniya², C. Campbell², S.G. Ray¹, N.H. Brooks¹, N.Yonan², Departments of ¹Cardiology and ²Cardiac Transplantation, Wythenshawe Hospital, Manchester, United Kingdom

(217) *Left Atrial Thrombosis and Systemic Embolism After Heart Transplantation. Can the Bicaval Technique Avoid This Serious Problem?*, D. Metras, A. Riberi, B. Kreitmann, P. Ambrosi, G. Habib, La Timone Children's Hospital, Marseilles, France

(218) *Cardiac Rejection Monitoring by Pulsed-Wave Tissue Doppler Imaging: Sensitivity, Specificity, Predictive Value and Particulars Related to the Post-Transplant Time*, M. Dandel, M. Hummel, J. Mueller, R. Meyer, R. Ewert, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany

(219) *Relationship of Hypogammaglobulinemia to Acute Cellular Rejection and Infection Following Cardiac Transplantation: Importance of IgG Level Monitoring*, M.H. Yamani, R.C. Starling, R.K. Avery, S.D. Mawhorter, M. Goormastic, P.M. McCarthy, J.B. Young, Cleveland Clinic Foundation, Cleveland, OH

(220) *Malignancies After Cardiac Transplant: A Single Center 13-Year Experience*, M.T. Olivari, S. Carlson, M.R. Pritzker, F.M. Hoffman, K. Gilkerson, R. Burns, J. Burdine, R.W. Emery, Abbott Northwestern Hospital, Minneapolis Heart Institute, Minneapolis, MN

(221) *Screening for Solid Organ Malignancies Prior to Cardiac Transplantation*, V. Conraads, A. Vorlat, A. Moulijn¹, C. Vrints, Departments of Cardiology and ¹Cardiac Surgery, University Hospital Antwerp, Antwerp, Belgium

(222) *How Far Do Patients Travel for Cardiac Transplantation? Analysis of a Current National Cohort*, C. Jones, C.A. Rogers, K. Breadmore, A.C. Anyanwu, A.J. Murday on behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons, London, UK

(223) *What are the Infectious Risks of Pets Immediately After Heart Transplant?*, J.M. Chuang, J.A. Kobashigawa, M. Mui, S. Lackey, R. Camara, J.D. Moriguchi, N. Kawata, M. Marks, A. Velleca, M. Brown, H. Laks, University of California, Los Angeles, CA

Moderator: Frances Pagani, MD

(224) *VEGF Transfected H9C2 Cell Transplantation to the Infarcted Myocardium*, K. Inui, Y. Shimazaki, T. Sugimoto, T. Watanabe, T. Takahashi, T. Minowa, J. Hosaka, Second Department of Surgery, Yamagata University School of Medicine, Yamagata City, Japan

(225) *Surgical Anterior Ventricular Reconstruction (SAVR) for Ischemic and Idiopathic Dilated Cardiomyopathy*, T. Doenst¹, L. Ahn-Veelken¹, P. Dern¹, K. Sarai¹, M. Schafer², A. van de Loo², F. Beyersdorf¹, ¹Department of Cardiovascular Surgery and ²Department of Cardiology, University of Freiburg, Freiburg, Germany

(226) *CTLA4IG-Gene Transfection by Adenoviral Vector Prolonged the Rat Cardiac Allograft Survival. The Mechanisms of This Therapy*, Y. Kita, X.K. Li, M. Ohba, H. Nogimura, Y. Kageyama, S. Ohi, K. Matsushita, K. Suzuki, S. Suzuki, T. Kazui, First Department of Surgery, Hamamatsu University School of Medicine, Haibara General Hospital, Shizuoka, and Department of Experimental Surgery and Bioengineering, National Children's Medical Research Center, Tokyo, Japan

(227) WITHDRAWN

(228) *Caution in the Interpretation of Release of Myocardial Contractile Proteins During Rejection*, N.B. Ratliff, J.L. Myles, J. McMahon, The Cleveland Clinic Foundation, Cleveland, OH

(229) *Diagnosing Pig-To-Primate Cardiac Xenograft Rejection With an Implantable Telemetric Monitoring Device: Histological and Immunohistochemical Correlations*, R.H. Chen¹, A. Kadner¹, R.N. Mitchell², D. Santerre¹, D.H. Adams¹, ¹Department of Surgery and ²Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

(230) *Effect of Platelet Inhibition on Pulmonary Xenograft Survival*, G.L. Zorn III, T.D. Giorgio, K.S.A. Blair, S.M. Farley, R.E. Parker, Y. Shry, C.E. Baird, L.M. George, A.M. Azimzadeh, S.C. Robson¹, R.N. Pierson III, Vanderbilt University, Nashville, TN, and ¹Harvard University, Boston, MA

(231) *Natural Killer Cells Infiltration in Porcine Renal Xenograft Rejection Increased With Survival Time of the Graft*, C. Atkinson¹, J. Horsley, M. Goddard, B. Holmes, E. Cozzi, H. Davies, D. Quan, C. Bravery, E. McInnes, C. Vial, D. White, G. Chavez, ¹Laboratory of Pathology, Papworth Hospital, and Imutran, Cambridge, United Kingdom

Moderator: Jeffrey D. Hosenpud, MD

(232) *Enhancement of Cardiac Mitochondrial Enzymatic Activities Following Heat Stress*, I.A. Sammut, N. Latif, J. Jayakumar, R.T. Smolenski, T.E. Bates, M.H. Yacoub, Heart Science Centre, NHLI at Imperial College, Harefield Hospital, London, United Kingdom

(233) *Influence of Interferon Gamma Polymorphism on Cardiac Transplant Vasculopathy Development*, C.G. Densem, I.V. Hutchinson, S. Sheldon, N. Yonan, N.H. Brooks, Cardiothoracic Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom

(234) *Possible Role of Oncostatin M in Cardiac Allograft Vasculopathy*, S. Aziz¹, K. Strand², Y. Patel³, S. Rahman³, A. Ishida², T. Nishibe², C. Cardona², J. Murray-Wijelath², G. Savidge³, E. Wijelath², ¹Division of Cardiothoracic Surgery, University of Colorado, Denver, CO; ²Hope Heart Institute, Seattle, WA; and ³St. Thomas Hospital, London, United Kingdom

(235) *Expression of Metalloproteinases in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients With Rejection*, M. Tamm^{1,2}, M. Roth^{1,2}, H. Parson², M. Malouf¹, P. Chhajed¹, P. Johnson², J. Black², A. Glanville¹, ¹Heart Lung Transplant Unit, St. Vincent's Hospital, and ²Department of Pharmacology, University of Sydney, Sydney, Australia

(236) *New Therapeutic Approach in the Therapy of Chronic Rejection? ACE-and AT1-Blocker Reduce the Development of Chronic Rejection After Cardiac Transplantation in a Rat Model*, M. Richter, R. Grabs, D. Schramm, H. Richter, R. Autschbach, F.W. Mohr, Universitat Leipzig, Leipzig, Germany

(237) *Apoptosis Via Fas/Fas Ligand Interaction in Lung Allograft Acute and Chronic Rejection*, C.K. Wang, A.V. Wong, H.M. Wang, J.H. Qiao, L. Czer, A. Trento, Department of Cardiothoracic Surgery and Pathology, Cedars Sinai Medical Center, Los Angeles, CA

(238) *The Role of Antigen Presenting Cells in Obliterative Airway Disease*, A.M. Krasinskas, A.D. McLean, W.Y. Szeto, D. Kreisel, H. Petrowsky, S.H. Popma, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

(239) See Concurrent Session #9

Moderator: Martin Zamora, MD

(240) *Chest CT Scan for the Identification of Bronchiolitis Obliterans Syndrome Following Lung Transplantation*, R.C. Cook, G. Fradet, N.L. Muller, D. Chittock, R.D. Levy, Vancouver General Hospital, University of British Columbia Lung Transplant Program, Vancouver, British Columbia, Canada

(241) *Cardiopulmonary Transplantation for Congenital Heart Disease in the Adult*, F.A. Pigula, S. Gandhi, J. Ristich, K. McCurry, S.A. Webber, B.P. Griffith, R. Kormos, University of Pittsburgh, Pittsburgh, PA

(242) *Improvement of Pulmonary Preservation With the PAF-Antagonist BN 52021 (Ginkgolide B) in Clinical Lung Transplantation*, Th. Wittwer¹, P. Oppelt², U. Franke¹, A. Haverich², Th. Wahlers¹, ¹Friedrich-Schiller University, Jena, and ²Medical School Hannover, Hannover, Germany

(243) *Comparison of Incidence and Spectrum of Infections in Patients Treated With Four Different Immunosuppressive Protocols After Lung Transplantation*, H. Treede, H. Reichenspurner, B.M. Meiser, F. Kur, O. Deutsch, H. Furst, C. Vogelmeier, J. Briegel, B. Reichart, Munich University, Munich, Germany

(244) *Clinical Variables at Presentation that Predict Survival in Patients Treated With Epoprostenol for Pulmonary Hypertension*, B.K. Rayburn, A.J. Newman, R.L. Benza, B.A. Foley, M.F. Aaron, R.C. Bourge, University of Alabama, Birmingham, AL

(245) *Orthotopic Heart and Heart-Lung Transplantation for Locally Advanced Cardiac Tumors*, M.A. Bade, H.A. Rajasinghe, A. Benjaminovitz, M.E. Galantowicz, L.L. Schulman, P. Sinha, D.J. Goldstein, E.A. Rose, N.M. Edwards, Columbia University, New York, NY

(246) *Activation of Caspases and DNA Fragmentation Factor in Patients with Heart Failure*, N. Latif, E. Birks, M.A. Khan, A.O. Farrell, M.J. Dunn, M.H. Yacoub, Heart Science Centre, NHLI at Imperial College, Harefield Hospital, Middlesex, United Kingdom

(247) *Cardiac Type VIII Collagen mRNA is Downregulated in Advanced Heart Failure*, M.C. Deng¹, G. Plenz, D. Borgmeier¹, T.D.T. Tjan¹, B. Asfour¹, H. Robenek, D. Hammel¹, H.H. Scheld¹, Institute of Arteriosclerosis Research, Division of Cell Biology and Ultrastructural Research, and ¹Department of Cardiothoracic Surgery, Muenster University Hospital, Muenster, Germany

(248) *Elimination of Cheyne-Stokes Respiration After Cardiac Transplantation in Patients with Severe End-Stage Congestive Heart Failure*, R.A. Sangrigoli, T.J. Berger, G. D'Alonzo, S.L. Krachman, H.J. Eisen, Temple University School of Medicine, Philadelphia, PA

MODERATED POSTERS

SESSION 2 (Event Hall 2)

Friday, April 7, 2000

5:30 pm – 6:30 pm

(Session 2 Moderated Posters will be on display in Event Hall 2 from 10:00 am – 6:30 pm on Friday, April 7.

Moderated Poster Session 2 authors will be available to answer questions about their posters during the wine and cheese reception from 5:30 pm – 6:30 pm on Friday, April 7.)

Moderator: Branislav Radovancevic, MD

(249) *Use of Mechanical Assist to Bridge Pediatric Patients With Severe End Stage Heart Disease to Transplantation*, D. Marelli, C. Eisenring, H. Laks, A. Sadeghi, M. Plunkett, D. Fazio, M. Talamo, J. Alejos, A. Galindo, C. Burch, University of California, Los Angeles, CA

(250) *Left Ventricular Assist Device Preserves Nitric Oxide Dependent Control of Mitochondrial Respiration in Failing Human Hearts*, S. Mital, K.E. Loke, L. Addonizio, M. Oz, T.H. Hintze, Columbia University College of Physicians and Surgeons, New York, and New York Medical College, Valhalla, NY

(251) *Predictors of Survival in Patients Bridged to Cardiac Transplantation with the Thoratec VAD Device. A Single Center Retrospective Study on More Than 100 Patients*, A. El-Banayosy, L. Arusoglu, L. Kizner, G. Tenderich, M.M. Körner, M. Morshuis, U. Schütt, K. Minami, R. Korfer, Department of Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany

(252) *Long-Term Performance of a Wearable Electrical Left Ventricular Assist System: A Clinical Study*, D. Wheeldon, D. LaForge, J. Lee, P. Jansen, J. Jassawalla, P. Portner, Baxter Healthcare, Novacor Division, Oakland, CA

(253) *Outcomes of LVAD Bridge Therapy for Acute Myocardial Infarction vs End-Stage Heart Failure*, S.J. Park, D.Q. Nguyen, S. Ormaza, L. Miller, R.M. Bolman III, University of Minnesota, Minneapolis, MN

(254) *Protection and Resuscitation of Non-Beating Hearts: A Potential Approach to Increase the Donor Pool*, P.A. Fedalen, V. Piacentino III, D.A. Popowich, C.A. Fisher, J.P. Gaughan, V. Jeevanandam, B.I. Goldman, K.B. Margulies, S. Furukawa, S.R. Houser, Temple University Health Sciences Center, Philadelphia, PA

(255) *The Use of Dialysis Dependent Donors for Lung Transplantation*, J.V. Conte, L. Ferber, M.C. Borja, J.B. Orens, S.C. Yang, Johns Hopkins Hospital, Baltimore, MD

(256) *Ventriculo-Arterial Coupling in the Brain Dead Organ Donor*, G. Szabó, C. Sebening, T. Hackert, V. Vuhmann, A. Graf, C.F. Vahl, S. Hagl, University of Heidelberg, Heidelberg, Germany

Moderator: Bruce Rosengard, MD

(257) *Effect of Interleukin-10 Polymorphism on Cardiac Transplant Vasculopathy*, C.G. Densem, I.V. Hutchinson, A. Cooper, N. Yonan, N.H. Brooks, Cardiothoracic Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom

(258) *Ischemic Preconditioning Improves Lung Function After Warm Ischemia in Dogs*, I. Friedrich¹, J. Spillner², J. Borgermann², E. Lu², T. Ley², A. Sablotzki¹, M. Barnscheid², J.C. Reidemeister², ¹Thoracic and Cardiovascular Surgery, Martin-Luther-Universitaet, Halle, and ²Thoracic and Cardiovascular Surgery, Universitaet Essen Medical School, Essen, Germany

(259) *Persistent Expression of Intra-Cardiac TNF α in Heart Transplant Recipients*, G. Torre-Amione, S.J. Stetson, B. Bruckner, M.M. Koerner, D. Weilbaecher, J.A. Farmer, G.P. Noon, M.L. Entman, Baylor College of Medicine, Houston, TX

(260) *Early Reperfusion Injury in Hearts From Brain Dead Donors Accelerates Acute Rejection of Rat Cardiac Allografts*, M.J. Wilhelm^{1,3}, J. Pratschke¹, M. Taal², F. Beato², C. Schmid³, H.H. Scheld³, N.L. Tilney¹, ¹Surgical Research Laboratory, Department of Surgery and ²Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ³Department of Cardiothoracic Surgery, University of Munster, Munster, Germany

(261) *CD8⁺ Lymphocytes Accentuate Cardiac Allograft Vasculopathy Via Crosspriming*, M.P. Fischbein, J. Yun, H. Laks, Y. Irie, M.C. Fishbein, M. Espejo, B. Bonavida, A. Ardehali, University of California, Los Angeles, CA

(262) *Combined Inhibition of TNF-ALPHA, TNF-BETA and IL-6 Abolishes Post-Transplant Airway Obliteration in Knock Out Mice*, P. Sandera^{1,3}, R.A. Schmid¹, H.P. Eugster², S. Hilinger¹, R. Speich³, E.W. Russi³, W. Weder¹, A. Fontana², A. Boehler³, Divisions of ¹Thoracic Surgery, ²Clinical Immunology and ³Pulmonary Medicine, University Hospital, Zurich, Switzerland

(263) *The Impact of Brain Death on the Immune Response After Transplantation: Induction of Different Proinflammatory Mediators in Chronic Rat Cardiac Allograft Rejection*, M.J. Wilhelm^{1,3}, J. Pratschke¹, W.W. Hancock², C. Schmid³, H.H. Scheld³, N.L. Tilney¹, ¹Surgical Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²LeukoSite Inc., Cambridge, MA; and ³Department of Cardiothoracic Surgery, University of Muenster, Muenster, Germany

Moderator: John Conte, MD

(264) *The Measurement of Reduced Cytochrome A,A3 in Cadaveric Lungs by Near-Infrared Spectroscopy*, S. Okimasa, T. Noriyuki, Y. Miyata, S. Shibata, S. Yoshioka, T. Ashara, H. Kajihara¹, Second Department of Surgery and ¹Institute of Health Science, Hiroshima University, Faculty of Medicine, Hiroshima, Japan

(265) *The Changing Profile of the Cardiac Donor*, M.V. Brock, D.E. Cameron, J. Salazar, W.A. Baumgartner, J.V. Conte, Johns Hopkins Hospital, Baltimore, MD

(266) *Do Donor Characteristics Really Matter? Analysis of 161 Consecutive Heart Donors*, J.M. Chen, H.A. Rajasinghe, P. Sinha, S.J. Suratwala, J.D. McCue, H.M. Hauff, R. John, N.M. Edwards, Columbia University, New York, NY

(267) *Raffinose Improves the Function of Rat Pulmonary Grafts Stored for 24 Hours in Low Potassium Dextran Solution*, S. Fischer, D. Hopkinson, M. Liu, S. Keshavjee, The Toronto Lung Transplant Program and the Thoracic Surgery Research Laboratory, The Toronto General Hospital, Toronto, Ontario, Canada

(268) *Improved Pulmonary Preservation With Celsior and Perfadex-Impact of Ischemic Time and Route of Administration*, Th. Wittwer¹, A. Fehrenbach², M. Ochs², H. Brandes¹, J. Albes¹, J. Richter², Th. Wahlers¹, ¹Friedrich-Schiller University, Jena, and ²University of Goettingen, Goettingen, Germany

(269) *The Effect of Nitroglycerin on Preservation of Infantile Heart: An Animal Study*, N. Haraguchi, T. Mastumoto, S. Morita, R. Tominaga, H. Yau, Kyushu University, Fukuoka, Japan

(270) *Does a High Potassium Concentration Directly Injure Cultured Human Pulmonary Artery Endothelial and Smooth Muscle Cells?*, T. Bessho¹, S. Miyoshi², Y. Naito¹, ¹Wakayama Medical College, Wakayama, ²Osaka University, Osaka, Japan

Moderator: Hector Ventura, MD

(271) *Epidemiology of Erectile Dysfunction in Heart Transplant Recipients and Role of Sildenafil in its Therapy*, J. Segovia, L.A. Pulpón, E. Cotrina, A. Bautista, I. Antorrena, E. Castedo, S. Serrano, J. Ugarte, Clínica Puerta de Hierro, Madrid, Spain

(272) *Response to Treatment of Hyperhomocysteinemia in Heart Transplant Recipients is Related to Renal Function*, R.C. Cook, S. Parker, K. Kingsbury, J.J. Frohlich, J.G. Able, M. Gao, A.P. Ignaszewski, University of British Columbia Heart Transplant Program, Healthy Heart Program, and Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada

(273) *Results of Tacrolimus in Cardiac Transplantation Following Intravenous Tacrolimus Administration* B.P. Madden for the European Tacrolimus Heart Study Group, Department of Cardiothoracic Surgery, St. George's Hospital, London, United Kingdom

(274) *Influence of Prolonged Cyclosporin Therapy on Insulin and its Precursors Secretion in Patients After Heart Transplantation*, M. Zakliczynski², T. Zielinska, M. Szewczyk², A. Zielinska-Kukla², J. Foremny², S. Pasyk, A. Religa¹, M. Zembala², Silesian Center of Heart Diseases, 1st Department of Cardiology, ¹1st Department of Cardiac Surgery, and ²Department of Transplantology, Silesian Medical School, Zabrze, Poland

(275) *Initial Experience With Orlistat as a Therapy for Refractory Obesity of Heart Transplant Recipients: Data on Efficacy and Interference With Cyclosporine*, J. Segovia, L.A. Pulpón, E. Cotrina, I. Antorrena, A. Bautista, E. Castedo, S. Serrano, J. Ugarte, Clínica Puerta de Hierro, Madrid, Spain

(276) See Concurrent Session 14

(277) *Early Endothelial Dysfunction on Cyclosporine Following Heart Transplantation*, A. Beniaminovitz, R.M. Di Tullio, O. Olufunso, S. Homma, D. Mancini, S. Kats, Columbia University, New York, NY

(278) *Sulfinpyrazone Reduces Cyclosporine-A Levels: A New Drug Interaction in Heart Transplant Recipients*, A.L.P. Caforio¹, A. Gambino², F. Tona³, F. Marchini⁴, E. Pompei², G. Feltrin², L. Testolin², A. Angelini⁴, S. Dalla Volta¹, D. Casarotto², ¹Cardiology, ⁴Pathology, ³Nephrology, and ²Cardiac Surgery, Padua University, Padua, Italy

(279) *Prediction of Cyclosporine Blood Levels in Heart Transplantation Patients Using an Artificial Intelligence Based Computation Technique*, M.R. Hoda¹, H. Mach², A. Zuckermann¹, M. Ploner¹, G. Laufer¹, ¹Department of Cardiothoracic Surgery, University Medical School of Vienna, and ²EVIS Technologies Inc., Vienna, Austria

(280) *Cytomegalovirus and Herpes Zoster Infections in Cardiac Transplant Recipients Treated With Mycophenolate Mofetil*, B. Czarska, R. del Busto, T. Sheppard, C. Drost, D. Rickeard, G. Franklin, C. Nelson, R.S. Higgins, E.F. Philbin, Henry Ford Hospital, Detroit, MI

(281) *High Rejection Score in the First Year is Associated With Increased Risk of Skin Cancer in Heart Transplantation*, A.L.P. Caforio², A. Belloni Fortina¹, A. Gambino³, S. Piaserico¹, F. Tona², G. Feltrin³, G. Tiene⁴, S. Dalla², D. Casarotto³, A. Peserico¹, ¹Dermatology, ²Cardiology, ⁴Pathology, and ³Cardiac Surgery, Padua University, Padua, Italy

LIST OF EXHIBITORS

Acorn Cardiovascular, Inc.
601 Campus Drive
St. Paul, MN 55112
Mid Jensen
Phone: 651-286-4858

Biotest Pharma GmbH
Landsteinerstr.5
Dreieich, Germany D-63303
Wilhelm Schneider
Phone: 49-6103-801-462

CardioWest Technologies, Inc.
1992 East Silverlake Road
Tucson, AZ85713
Steven R. Langford
Phone: 520-694-5222

MAXXIM Medical
Mr. Gerald F. Longo, c/o Circon
300 Stillwater Ave.
Stamford, CT 06902
Phone: 203-328-8772

Roche
PBC-CS, Bldg.74/Room 4-O
4070 Basel Switzerland
Nicole Fueglistaller
Phone: 41-61-687-8749

Thermo Cardiosystems Inc.
470 Wildsood Street
Woburn, MA 01888
Cindy Barstow
Phone: 978-251-2198

Thoratec Laboratories Corporation
6035 Stoneridge Drive
Pleasanton CA 94588
Luis Saravia
Phone: 925-847-8600

VITROLIFE
Molndalsvagen 30
Goteborg 41263 Sweden
Beatrice Adahl
Phone: 46-31-721-8063

Osato Research Institute
1956 Inatomi Ohno, Ibi
Gihu 5010501 Japan
Takagi
Phone: 81-585-34-3830

Fujisawa Pharmaceutical Co., Ltd.
3-4-7 Doshomachi Chuo-ku
Osaka 5418514 Japan

Masato Asai
Phone: 81-6-6206-0122

Novartis Pharma
4-17-30 Nishiazabu
Minato-ku Tokyo 1068618 Japan
Yasuko Iinuma
Phone: 81-3-3797-8739

Baxter Cardiovascular Group
6-4 Chiyoda-ku
Tokyo 1028468 Japan
Sato
Phone: 81-3-5213-5700

COSMOTEC Co., Ltd
1-46 Toyotsu
Suita, Osaka 5640051
Egawa
Phone: 81-3-5802-3830

GE Marquette Medical Systems Japan
Nihonseimei Gotanda Bldg.
1-31-1 Nishigotanda
Shinagawa Tokyo 1410031
Yoshida
Phone: 81-3-3495-6584

KONO SEISAKUSHO CO., LTD
3-30-10 Hongo Bunkyo-Ku
Tokyo 1130033 Japan
Matsumoto
Phone: 81-3-3813-7411

SENKO MEDICAL INSTRUMENT MFG CO., LTD
3-23-13 Hongo Bunkyo-ku
Tokyo 1130033 Japan
Hashimoto
Phone: 81-3-3812-3254

TAISHO BIOMED INSTRUMENTS CO., LTD
4-16-18-2F 4-16-18 Sangenyahigashi
Taisho-ku Osaka
Osaka 5510002 Japan
Tanaka
Phone: 81-6-6553-9666

UBE MEDICAL CO., LTD.
Exeed Esaka Bldg. 1-46 Toyotsu
Suita, Osaka 564-0051
Phone: 81-6-6330-6761

ZEON MEDICAL, Inc.
Shuwa Park Bldg. B3F, 2-4-1 Shiba-Koen
Minato-ku Tokyo 1050011 Japan
Yasuda
Phone: 81-3-3578-7726

Future ISHLT Meetings

April 25-29, 2001
ISHLT 21st Annual Meeting and Scientific Sessions
Vancouver, BC, Canada

April 10-13, 2002
ISHLT 22nd Annual Meeting and Scientific Sessions
Washington, DC



14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
Email: ishlt@ishlt.org
Http:\\www.ishlt.org